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A B S T R A C T
Background
Screening hysteroscopy in infertile womenwith unexplained infertility, or prior to intrauterine insemination (IUI) or in vitro fertilisation
(IVF) may reveal intrauterine pathology that may not be detected by routine transvaginal ultrasound. Hysteroscopy, whether purely
diagnostic or operative may improve reproductive outcomes.
Objectives
To assess the effectiveness and safety of screening hysteroscopy in subfertile women undergoing evaluation for infertility, and subfertile
women undergoing IUI or IVF.
Search methods
We searched the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL CRSO, MEDLINE, Embase, Clinical-
Trials.gov, and theWorldHealth Organization International Clinical Trials Registry Platform (September 2018). We searched reference
lists of relevant articles and handsearched relevant conference proceedings.
Selection criteria
Randomised controlled trials comparing screening hysteroscopy versus no intervention in subfertile women wishing to conceive
spontaneously, or before undergoing IUI or IVF.
Data collection and analysis
We independently screened studies, extracted data, and assessed the risk of bias. The primary outcomes were live birth rate and
complications following hysteroscopy. We analysed data using risk ratio (RR) and a fixed-effect model. We assessed the quality of the
evidence by using GRADE criteria.
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Main results
We retrieved 11 studies.We included one trial that evaluated screening hysteroscopy versus no hysteroscopy, in women with unexplained
subfertility, whowere trying to conceive spontaneously.We are uncertainwhether ongoing pregnancy rate improves following a screening
hysteroscopy in women with at least two years of unexplained subfertility (RR 4.30, 95% CI 2.29 to 8.07; 1 RCT; participants =
200; very low-quality evidence). For a typical clinic with a 10% ongoing pregnancy rate without hysteroscopy, performing a screening
hysteroscopy would be expected to result in ongoing pregnancy rates between 23% and 81%. The included study reported no adverse
events in either treatment arm. We are uncertain whether clinical pregnancy rate is improved (RR 3.80, 95% CI 2.31 to 6.24; 1 RCT;
participants = 200; very low-quality evidence), or miscarriage rate increases (RR 2.80, 95% CI 1.05 to 7.48; 1 RCT; participants =
200; very low-quality evidence), following screening hysteroscopy in women with at least two years of unexplained subfertility.
We included ten trials that included 1836womenwho received a screening hysteroscopy and 1914womenwho received no hysteroscopy
prior to IVF.Main limitations in the quality of evidence were inadequate reporting of study methods and higher statistical heterogeneity.
Eight of the ten trials had unclear risk of bias for allocation concealment.
Performing a screening hysteroscopy before IVF may increase live birth rate (RR 1.26, 95% CI 1.11 to 1.43; 6 RCTs; participants =
2745; I² = 69 %; low-quality evidence). For a typical clinic with a 22% live birth rate, performing a screening hysteroscopy would be
expected to result in live birth rates between 25% and 32%. However, sensitivity analysis done by pooling results from trials at low risk
of bias showed no increase in live birth rate following a screening hysteroscopy (RR 0.99, 95% CI 0.82 to 1.18; 2 RCTs; participants
= 1452; I² = 0%).
Only four trials reported complications following hysteroscopy; of these, three trials recorded no events in either group.We are uncertain
whether a screening hysteroscopy is associated with higher adverse events (Peto odds ratio 7.47, 95% CI 0.15 to 376.42; 4 RCTs;
participants = 1872; I² = not applicable; very low-quality evidence).
Performing a screening hysteroscopy before IVF may increase clinical pregnancy rate (RR 1.32, 95% CI 1.20 to 1.45; 10 RCTs;
participants = 3750; I² = 49%; low-quality evidence). For a typical clinic with a 28% clinical pregnancy rate, performing a screening
hysteroscopy would be expected to result in clinical pregnancy rates between 33% and 40%.
There may be little or no difference in miscarriage rate following screening hysteroscopy (RR 1.01, 95% CI 0.67 to 1.50; 3 RCTs;
participants = 1669; I² = 0%; low-quality evidence).
We found no trials that compared a screening hysteroscopy versus no hysteroscopy before IUI.
Authors’ conclusions
At present, there is no high-quality evidence to support the routine use of hysteroscopy as a screening tool in the general population of
subfertile women with a normal ultrasound or hysterosalpingogram in the basic fertility work-up for improving reproductive success
rates.
In women undergoing IVF, low-quality evidence, including all of the studies reporting these outcomes, suggests that performing a
screening hysteroscopy before IVF may increase live birth and clinical pregnancy rates. However, pooled results from the only two trials
with a low risk of bias did not show a benefit of screening hysteroscopy before IVF.
Since the studies showing an effect are those with unclear allocation concealment, we are uncertain whether a routine screening
hysteroscopy increases live birth and clinical pregnancy, be it for all women, or those with two or more failed IVF attempts. There is
insufficient evidence to draw conclusions about the safety of a screening hysteroscopy.
P L A I N L A N G U A G E S U M M A R Y
Screening hysteroscopy in subfertile women trying to conceive spontaneously, and before in vitro fertilisation
Review question
To assess the safety and usefulness of performing a screening hysteroscopy on reproductive outcomes in women trying to conceive
spontaneously, and those undergoing in vitro fertilisation (IVF).
Background
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In women with an unexplained problem in becoming pregnant, or those seeking advanced fertility treatment, such as intrauterine
insemination or IVF, it has been suggested that performing a hysteroscopy (visualisation of the inside of the womb, using a telescope)
may help improve success. The routine ultrasound done during the work-up may miss smaller abnormalities inside the womb, which
may be detected and treated simultaneously by performing a hysteroscopy. It may also increase success by facilitating the subsequent
insemination or embryo transfer, by widening the passage to the womb (cervical dilatation), or because of a scratching effect on the
endometrium (lining of the womb), which may help to improve embryo implantation (adherence to lining of womb).
Study characteristics
For women wishing to become pregnant spontaneously, we found one trial (200 women). For women undergoing IVF, we included
ten trials (3750 women). All trials evaluated the effects of screening hysteroscopy compared to no hysteroscopy. The evidence is current
to September 2018.
Key results
In women wishing to become pregnant spontaneously, hysteroscopy was associated with a higher chance for an ongoing and clinical
pregnancy in one study at high risk of bias. The trial reported no adverse events following hysteroscopy. The miscarriage rate was higher
following hysteroscopy.
In women undergoing IVF, the included studies suggested that performing a screening hysteroscopy first, improved the chances of live
birth or clinical pregnancy. However, adverse events following hysteroscopy were poorly reported, and therefore, we were unable to
assess the safety of this intervention. For women at a typical clinic with a 22% live birth rate, performing a screening hysteroscopy would
be expected to result in live birth rates between 25% and 32%. There was no increased risk of miscarriage following hysteroscopy.
We found no trials with women who were seeking intrauterine insemination.
Quality of the evidence
There was very low-quality evidence from one study in women who were trying to become pregnant spontaneously.
There was low-quality evidence that a screening hysteroscopy, performed prior to IVF, may increase the chance of live birth or clinical
pregnancy, and very low-quality evidence about adverse events following hysteroscopy. The quality of the evidence was reduced because
of risk of bias and statistical heterogeneity.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hysteroscopy compared with no hysteroscopy in women wishing to conceive spontaneously
Patient or population: women with unexplained subfert ility wishing to conceive spontaneously
Settings: Arafa Hospital, Fayoum, Egypt
Intervention: screening hysteroscopy
Comparison: no hysteroscopy
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no hys-
teroscopy
Risk with hysteroscopy
Live birth 100 per 1000 430 per 1000
(229 to 807)
RR 4.30
(2.29 to 8.07)
200
(1 RCT)
⊕⊕©©
very lowa,b
Adverse events 0 per 1000 0 per 1000
(0 to 0)
not est imable (1 RCT) ⊕©©©
very lowa,b.c
Clinical pregnancy 150 per 1000 570 per 1000
(347 to 936)
RR 3.80
(2.31 to 6.24)
200
(1 RCT)
⊕⊕©©
very lowa,b
Miscarriage 50 per 1000 140 per 1000
(52 to 374)
RR 2.80
(1.05 to 7.48)
200
(1 RCT)
⊕©©©
very lowa,b,c
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
According to the International Committee for Monitoring As-
sistedReproductiveTechnology (ICMART) and theWorldHealth
Organization’s (WHO) revised glossary of assisted reproductive
technology, subfertility is “a disease of the reproductive system, de-
fined by the failure to achieve a clinical pregnancy after 12 months
or more of regular unprotected sexual intercourse, or due to an
impairment of a person’s capacity, either as an individual, or with
his or her partner” (Zegers-Hochschild 2017). It is estimated that
72.4 million women are subfertile, and that 40.5 million of these
are currently seeking fertility treatment (Boivin 2007). A basic
subfertility evaluation comprises tests for ovulation, tubal patency,
and a transvaginal ultrasound to rule out uterine or ovarian pathol-
ogy for the female partner, and semen analysis for the male part-
ner (ASRM 2016). The evaluation of the uterine cavity could be
considered an important step in the investigation of all subfertile
women, as the uterine cavity and its inner layer, the endometrium,
are assumed to be important for implantation of the human em-
bryo.
In women undergoing in vitro fertilisation (IVF), despite numer-
ous technological advances, live-birth rates are between 21% and
25% (Mansour 2014; EIM/ESHRE2016). Even after transferring
euploid embryos following pre-implantation genetic screening,
pregnancy rate is only around 64% (Fiorentino 2014). Embryo
implantation remains one of the crucial steps that determines the
success of an IVF cycle. The successful implantation is dependent
on embryo-uterine ’cross talk’, which is mediated through various
factors, such as cytokines, growth factors, and adhesion molecules
(Singh 2011; Zhang 2013). Uterine factors, such as polyps and
adhesions, may negatively impact the outcomes of IVF (Taylor
2008).
Description of the intervention
Hysteroscopy can both evaluate the uterine cavity for pathology,
and either during the same procedure or in a further procedure,
treat polyps, adhesions, septa, andfibroids. Screeninghysteroscopy
is carried out in asymptomatic women, with no detectable uterine
cavity abnormalities on pelvic imaging. Hysteroscopy is a com-
monly performed gynaecological procedure with low complica-
tion rates (0.1% to 0.95% (Jansen 2000)). It can be carried out
in an outpatient setting without general or regional anaesthesia.
Various methods of pain relief are used, such as local, oral, or intra-
venous analgesia, either alone or in combination (Ahmad 2017).
It is considered the gold standard for the diagnosis of uterine cavity
pathology (Taylor 2008; Bosteels 2015).
Hysteroscopy allows the direct visualisation of the uterine cavity
through a rigid, semi-rigid, or flexible endoscope. During hys-
teroscopy, the instrument is passed through the cervix into the
uterine cavity. For optimal visualisation, a distension medium,
commonly saline, is used to expand the uterine cavity. The hys-
teroscope consists of a rigid telescope with a proximal eyepiece, and
a distal objective lens that can be angled at 0° to allow direct view-
ing, or offset at various angles to provide a forward-oblique view.
The total working diameters of modern diagnostic hysteroscopes
are typically 2.5 to 4.0 mm. Operative hysteroscopy requires ad-
equate visualisation through a continuous fluid circulation using
an in- and outflow channel. The outer diameters of modern op-
erative hysteroscopes have been reduced to a diameter of between
4.0 and 5.5mm. The sheath system contains one or two 1.6 to 2.0
mm working channels for the insertion of small biopsy forceps,
scissors, retraction loops and morcellators, or unipolar or bipolar
electro diathermy instruments.
In clinical practice, evaluation of the uterine cavity is usually done
with a transvaginal ultrasound scan (TVS) prior to IVF. Due to
the perceived advantages of hysteroscopy over TVS, such as the
potential for simultaneous detection and treatment of intrauterine
pathologies, use of a pre-IVF screening hysteroscopy has gained
widespread acceptance (Campo 2014).
How the intervention might work
It is assumed that uterine cavity abnormalities may interfere with
factors that regulate the embryo-endometrium interplay, for ex-
ample, hormones and cytokines, reducing the possibility of preg-
nancy. Many hypotheses have been formulated in the literature
as to how endometrial polyps, submucous fibroids, intrauterine
adhesions, and uterine septa may impair implantation of the hu-
man embryo; nevertheless, the precise mechanisms of the action
through which each one of these cavity abnormalities affects this
essential reproductive process are poorly understood.
Screening hysteroscopy in woman prior to IVF may reveal in-
trauterine pathology thatmay not be detected by routineTVS.The
reported rate of intrauterine pathology is 12% in women undergo-
ing first IVF (Smit 2016), and 27% in women with recurrent im-
plantation failure (RIF) (El-Toukhy 2016). Hysteroscopy allows
detection and treatment of many of these intrauterine pathologies,
which may improve IVF outcomes (Oliveira 2003). Cervical dila-
tion during pre-IVF hysteroscopy may facilitate subsequent em-
bryo transfers, which could possibly improve outcomes. Another
proposed mechanism to help improve IVF outcomes following
hysteroscopy is local endometrial injury caused during the invasive
procedure. The inflammatory reaction following endometrial in-
jury leads to a release of cytokines and growth factors, which may
help implantation and improve clinical pregnancy rates following
IVF (Barash 2003; Nastri 2015).
Why it is important to do this review
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Although detection of intrauterine pathologies in women with
normal TVS prior to IVF is perceived as one of the benefits of per-
forming hysteroscopy, we wish to evaluate whether treating these
pathologies improves outcomes following IVF (Oliveira 2003;
Pundir 2014; Smit 2016). Current guidelines do not advocate the
routine use of screening hysteroscopy during the initial infertil-
ity work-up (Crosignani 2000; NICE 2013). Due to uncertainty
about the role of screening hysteroscopy in women with normal
TVS during infertility work-up, and prior to IVF, it is important
to conduct a systematic appraisal of the current evidence.
O B J E C T I V E S
To assess the effectiveness and safety of screening hysteroscopy in
subfertile women undergoing evaluation for infertility and sub-
fertile women undergoing intrauterine insemination (IUI) or in
vitro fertilisation (IVF).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCT)
were eligible for inclusion. We excluded non-randomised studies
and quasi-randomised trials.
Types of participants
1. Subfertile women, with otherwise unexplained infertility, in
whom routine imaging did not show uterine cavity
abnormalities, who wished to conceive spontaneously
2. Subfertile women, in whom routine imaging did not show
uterine cavity abnormalities, and before treatment with IUI.
3. Women in whom routine imaging did not show uterine
cavity abnormalities, and before treatment with IVF.
We excluded subfertile women with suspected uterine cavity ab-
normalities (present on any imaging techniques), as this topic is
covered by another Cochrane review (Bosteels 2015).
Types of interventions
We included the following three randomised comparisons:
1. A routine screening hysteroscopy, with or without
treatment of any detected uterine cavity abnormalities, versus no
hysteroscopy, in subfertile women wishing to conceive
spontaneously.
2. A routine screening hysteroscopy, with or without
treatment of any detected uterine cavity abnormalities, versus no
hysteroscopy, before intrauterine insemination (IUI).
3. A routine screening hysteroscopy, with or without
treatment of any detected uterine cavity abnormalities, versus no
hysteroscopy, before in vitro fertilisation (IVF).
Types of outcome measures
Primary outcomes
1. Live birth or (in studies that do not report live birth)
ongoing pregnancy. The live-birth delivery rate (whether or not
after assisted reproduction) was defined as delivery of a live foetus
after 20 completed weeks of gestational age. We counted the
delivery of singleton, twin, or multiple pregnancies as one live
birth. The ongoing pregnancy rate (whether or not after assisted
reproduction) was defined as evidence of a gestational sac with
foetal heart motion at 12 weeks, confirmed by ultrasound. We
counted multiple gestational sacs as one ongoing pregnancy. We
used ongoing pregnancy as a surrogate outcome for live birth.
2. Adverse events: the incidence of complications due to the
hysteroscopy procedure, analysed as a composite measure of any
adverse events (including perforation, infection, vasovagal
attacks).
Secondary outcomes
1. Clinical pregnancy rate (whether or not after assisted
reproduction), defined as ultrasound evidence of a gestational sac.
2. Miscarriage rate (whether or not after assisted
reproduction), defined as the spontaneous loss of a clinical
pregnancy that occurred before 20 completed weeks of gestation
(18 weeks post-fertilisation) or, if gestational age was unknown,
the loss of an embryo or foetus of less than 400 grams.
We did not exclude studies on the basis of their reported outcome
measures. We reported any lack of data for key outcomes in the
final results and discussion.
Search methods for identification of studies
We searched for all published and unpublished RCTs of routine
hysteroscopy in infertile women, without language restriction,
and in consultation with the Cochrane Gynaecology and Fertility
Group (CGF) Information Specialist.
Electronic searches
We searched the following electronic databases, trial registers, and
web sites from inception to 05 September 2018:
• Cochrane CGF Specialised Register, ProCite platform,
searched 05 September 2018 (Appendix 1);
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• Cochrane Central Register of Studies (CENTRAL CRSO),
Web platform, searched 05 September 2018 (Appendix 2);
• MEDLINE, Ovid platform, searched from 1946 to 05
September 2018 (Appendix 3);
• Embase, Ovid platform, searched from 1980 to 05
September 2018(Appendix 4);
• PsycINFO, Ovid platform, searched from 1806 to 05
September 2018 (Appendix 5);
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), EBSCO platform, searched from 1961 to 05
September 2018 (Appendix 6);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Trials Registry
Platform ( www.who.int/trialsearch/Default.aspx);
• DARE ( Database of Abstracts of Reviews of Effects) on the
Cochrane Library for reference lists from relevant non-Cochrane
reviews ( onlinelibrary.wiley.com/o/cochrane/
cochrane cldare articles fs.html);
• Web of Knowledge ( another source of trials and conference
abstracts ( wokinfo.com/));
• OpenGrey for unpublished literature from Europe (
www.opengrey.eu/);
• LILACS ( Latin American and Caribbean Health Science
Information database) ( regional.bvsalud.org/php/index.php?
lang=en);
• PubMed and Google for recent trials not yet indexed in
MEDLINE.
We combined the MEDLINE search with the Cochrane Highly
Sensitive Search Strategy for identifying randomised trials, which
appears in Section 6.4.11 of the Cochrane Handbook for Systematic
Reviews of Interventions (Lefebre 2011).
We combined the Embase, PsycINFO, and CINAHL searches
with trial filters developed by the Scottish Intercollegiate Guide-
lines Network ( SIGN ( www.sign.ac.uk/search-filters.html)).
Searching other resources
Four review authors (SS, JB for non-IVF comparisons; SKS,MSK
for IVF comparison) handsearched reference lists of articles re-
trieved by the search, and contacted experts in the field to ob-
tain additional data. We also handsearched relevant journals and
conference abstracts that were not covered in the GFG register, in
liaison with the Information Specialist.
Data collection and analysis
Selection of studies
Two review authors (SS,MSK) conducted an initial screen of titles
and abstracts identified by the search, after which we retrieved the
full texts of all potentially eligible studies. Four review authors (SS,
JB, SSK, MSK) independently examined these full-text articles
for compliance with the inclusion criteria, and selected studies
eligible for inclusion in the review. We corresponded with study
investigators as required to clarify study eligibility. Disagreements
as to study eligibilitywere resolved by discussion or by a fifth review
author (BWJM). We documented the selection process with a
PRISMA flow chart.
Data extraction and management
Two methodologists (SS, MSK) and two topic area specialists (JB,
SSK) independently extracted data from eligible studies using a
data extraction form designed and pilot-tested by the review au-
thors. Any disagreement was resolved by discussion or by a fifth
review author (BWJM). We extracted data that included study
characteristics and outcome data (Appendix 7). We corresponded
with study investigators for further data on methods or results,
or both, as required. We included studies irrespective of whether
outcomes were reported in a ’usable’ way.
Assessment of risk of bias in included studies
Four review authors (SS, JB for non-IVF comparisons; SKS,MSK
for IVF comparison) independently assessed the included studies
for risk of bias using the Cochrane ’Risk of bias’ assessment tool
(Higgins 2011). We assessed the following items: selection (ran-
dom sequence generation and allocation concealment); perfor-
mance (blinding of participants and personnel); detection (blind-
ing of outcome assessors); attrition (incomplete outcome data);
reporting (selective reporting); and other bias. Disagreements were
resolved by discussion or by a fifth review author. We described
all judgements fully, and presented the conclusions in the ’Risk
of bias’ table, which were incorporated into the interpretation of
review findings by means of sensitivity analyses (see Sensitivity
analysis). Selective reporting is a type of reporting bias that affects
the internal validity of an individual study. It refers to the selective
reporting of some outcomes (e.g. positive outcomes) and the fail-
ure to report others (e.g. adverse events). We took care to search
for within-trial selective reporting, such as trials failing to report
obvious outcomes, or reporting them in insufficient detail to al-
low inclusion. We compared the outcomes between the published
protocol and the final published study. Where identified studies
failed to report the primary outcome of live birth, but did report
interim outcomes, such as clinical pregnancy, we undertook infor-
mal assessment as to whether the interim values (e.g. pregnancy
rates) were similar to those reported in studies that also reported
live birth.
Measures of treatment effect
For dichotomous data (e.g. live-birth rates), we used the number
of events in the control and intervention groups of each study
8Screening hysteroscopy in subfertile women and women undergoing assisted reproduction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to calculate risk ratios (RR). We used Peto odds ratio (OR) for
outcomes with low event rates. We reversed the direction of effect
of individual studies, if required, to ensure consistency across trials.
We presented 95% confidence intervals (CI) for all outcomes.
We compared the magnitude and direction of effect reported by
studies with how they were presented in the current review, taking
account of legitimate differences.
Unit of analysis issues
The primary analysis was per woman randomised; we included per
pregnancy data for some outcomes (for the outcome miscarriage).
We counted multiple live births (e.g. twins or triplets) as one live-
birth event.
Dealing with missing data
We analysed the data on an intention-to-treat basis to the greatest
degree possible, and attempted to obtain missing data from the
original authors. We assumed live births or clinical pregnancies
would not be present in women without a reported outcome. For
other outcomes, we analysed only the available data.
For Imputated data, we had planned to conduct sensitivity analysis
(see Sensitivity analysis).
Assessment of heterogeneity
We considered whether the clinical andmethodological character-
istics of the included studieswere sufficiently similar formeta-anal-
ysis to provide a clinicallymeaningful summary.We assessed statis-
tical heterogeneity using the I² statistic. An I²measurement greater
than 50% indicated substantial heterogeneity (Higgins 2011).
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, the review authors aimed to
minimise the potential impact of these biases by ensuring a com-
prehensive search for eligible studies, and by being alert for du-
plication of data. Since there were fewer than 10 studies in each
population, we did not use a funnel plot.
Data synthesis
Four review authors (SS, JB for non-IVF comparisons; SKS,MSK
for IVF comparison) entered the data and performed the statistical
analysis using Review Manager 5 (RevMan 2014). We combined
the data using a fixed-effect model for the following comparisons.
• Hysteroscopy versus no hysteroscopy for subfertile women
wishing to conceive spontaneously
• Hysteroscopy versus no hysteroscopy for subfertile women
undergoing IUI
• Hysteroscopy versus no hysteroscopy for women
undergoing IVF
We displayed an increase in the odds of a particular outcome,
whichmay be beneficial (e.g. live birth) or detrimental (e.g. adverse
effects of the hysteroscopy) graphically in the meta-analyses to the
right of the centre-line, and a decrease in the odds of an outcome
to the left of the centre-line.
Subgroup analysis and investigation of heterogeneity
We conducted the following subgroup analysis:
For women undergoing IVF:
• First IVF versus two or more IVF failures.
Sensitivity analysis
We conducted sensitivity analyses for the primary outcome live
birth and an important secondary outcome (clinical pregnancy
rate) to determine whether the conclusionswere robust to arbitrary
decisions made regarding eligibility and analysis. These analyses
included consideration of whether the review conclusions would
have differed if:
• eligibility had been restricted to studies without high or
unclear risk of bias in any domain;
• a random-effects model had been adopted;
• alternative imputation strategies had been implemented;
• the summary effect measure had been odds ratio rather
than risk ratio;
• the primary outcome had been limited to live birth.
Overall quality of the body of evidence: ’Summary of
findings’ table
We prepared a ’Summary of findings’ table using GRADEpro
GDT and Cochrane methods (GRADEproGDT;Higgins 2011).
This table evaluated the overall quality of the body of evidence for
all review outcomes (live birth, adverse events, clinical pregnancy,
and miscarriage), for the following comparisons: a screening hys-
teroscopy versus no hysteroscopy in subfertile women wishing to
conceive spontaneously; and a screening hysteroscopy versus no
hysteroscopy in women before IVF. We assessed the quality of the
evidence using GRADE criteria (risk of bias, consistency of ef-
fect, imprecision, indirectness, and publication bias). Two review
authors independently made judgements about evidence quality
(high, moderate, low, or very low), with any disagreements re-
solved by discussion. They justified, documented, and incorpo-
rated the judgments into report of results for each outcome.
We extracted study data, formatted our comparisons in data tables,
and prepared a ’Summary of findings’ table before writing the
results and conclusions of our review.
R E S U L T S
9Screening hysteroscopy in subfertile women and women undergoing assisted reproduction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of studies
Results of the search
We ran our electronic search on 05 September 2018. The targeted
search resulted in 761 records, out of which 227 were duplicate
records. Two teams of review authors (JB and SS; MSK and SSK)
screened the records simultaneously and independently, and ex-
amined the titles and abstracts to identify potentially eligible stud-
ies among the remaining 534 records.
After independent assessment, two authors (SS, JB) found five po-
tentially eligible studies for the randomised comparisons in sub-
fertile women wishing to conceive spontaneously, or before in-
trauterine insemination (IUI); we only included one trial (Seyam
2015). One study is awaiting classification (Moramezi 2012). We
excluded three trials for not addressing the research question of
interest (Brown 2000; El-Khayat 2015; Shokeir 2016). See the
’Characteristics of excluded studies’ tables.
Two authors (MSK, SSK) independently assessed studies that
evaluated screening hysteroscopy before in vitro fertilisation
(IVF), and found 24 records of potentially eligible studies.
We excluded seven trials (Fatemi 2010; Wang 2011; Kasius
2013; Kamel 2015; Zhang 2015; Hebeisha 2018; Siristatidis
2017), and included ten trials in the review (Demirol 2004;
Rama Raju 2006; El-Nashar 2011; Aghahosseini 2012; Shawki
2012; Elsetohy 2015; El-Toukhy 2016; Smit 2016; Alleyassin
2017; Juul Hare 2018). For two included trials, there were
two published protocols and one conference abstract (Smit
2016; El-Toukhy 2016). We identified four ongoing trials
(NCT02245750; NCT03173404; PACTR201402000691997;
UMIN000025679). See the ’Characteristics of ongoing studies’
tables.
When we combining all the populations we evaluated under this
review, we found 26 potentially eligible studies, out of which we
included 11 trials for quantitative synthesis. The search results are
summarized in the PRISMA flow chart (Figure 1).
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Figure 1. Study flow diagram
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Included studies
See ’Characteristics of included studies’ tables.
Design
We included a total of 11 randomised controlled trials (RCT)
in the review. Out of these 11 included trials, eight were com-
pleted and published as full articles (Demirol 2004; Rama Raju
2006; Shawki 2012; Elsetohy 2015; Seyam 2015; El-Toukhy
2016; Smit 2016; Alleyassin 2017), and three were conference
abstracts (El-Nashar 2011; Aghahosseini 2012; Juul Hare 2018).
Three weremulticentre trials, conducted in theNetherlands (Smit
2016), European centres (El-Toukhy 2016), and Denmark (Juul
Hare 2018). The remaining eight trials were single centre tri-
als. Two were conducted in Iran (Aghahosseini 2012; Alleyassin
2017), four in Egypt (El-Nashar 2011; Shawki 2012; Elsetohy
2015; Seyam 2015), one in India (Rama Raju 2006), and one in
Turkey (Demirol 2004).
One of the studies was partly funded by the European Society of
Human Reproduction and Embryology, the European Society for
Gynaecological Endoscopy (ESGE), and the Karl Storz Company
provided the hysteroscopy equipment for all centres (El-Toukhy
2016). TheDutchOrganisation forHealthResearch andDevelop-
ment (ZonMW) funded the other multicentre trial (Smit 2016).
The rest of the trials did not acknowledge any funding support.
Participants
Seyam 2015 enrolled 200 women with unexplained subfertility
who attended a single centre in Egypt. The basic work-up included
a hysterosalpingogram (HSG) and a transvaginal ultrasound to
screen for uterine pathology and tubal patency. The authors of
this RCT did not report whether or not a prior hysteroscopy or a
concomitant endometrial biopsy were done. We could not obtain
further clarification.
The characteristics of the participants among the IVF popu-
lation are shown in Table 1. Three trials included subfertile
women undergoing their first IVF (Elsetohy 2015; Smit 2016;
Alleyassin 2017). Four trials included women with two or more
IVF failures (Demirol 2004; RamaRaju 2006; Aghahosseini 2012;
El-Toukhy 2016). Two trials included an unselected IVF popula-
tion (El-Nashar 2011; Shawki 2012). One trial included women
with one IVF failure who were undergoing their second IVF treat-
ment (Juul Hare 2018). In six trials, participants had an addi-
tional radiological procedure, in the form of a HSG, as an in-
clusion criteria (Demirol 2004; Rama Raju 2006; Aghahosseini
2012; Shawki 2012; Elsetohy 2015; Alleyassin 2017). Two tri-
als excluded participants with a history of previous hysteroscopy
(Smit 2016; Alleyassin 2017); and one trial included women with
a previous history of hysteroscopy in both the intervention and
control arms (El-Toukhy 2016).
Interventions
Seyam 2015 randomly compared office microhysteroscopy ver-
sus no hysteroscopy in women with unexplained subfertility, for
a mean duration of two years. Hysteroscopy was done in the fol-
licular phase. When pathology was detected, treatment was done,
including hysteroscopic resection of endometrial polyps and sub-
mucous fibroids, and excision of a uterine septum.
Cycle characteristics of included studies of an IVF population are
shown in (Table 1). Among the IVF population, the hysteroscopy
was performed in the luteal phase in one trial (Alleyassin 2017),
and in the follicular phase in five trials (Demirol 2004; Rama
Raju 2006; Elsetohy 2015; El-Toukhy 2016; Smit 2016). In four
trials, the IVF was performed in the immediate cycle following
hysteroscopy (Demirol 2004; Rama Raju 2006; El-Toukhy 2016;
Alleyassin 2017); while in two trials, IVF was performed within
one to three months after hysteroscopy (Elsetohy 2015; Smit
2016). No information on timing of hysteroscopy was available
for four trials (El-Nashar 2011; Aghahosseini 2012; Shawki 2012;
Juul Hare 2018).
In three trials, hysteroscopy was combined with endometrial
biopsy in the intervention arm, but no procedure was done in
the control arm (Rama Raju 2006; El-Nashar 2011; Juul Hare
2018). In six trials, hysteroscopy was done in the intervention
arm, while no intervention was done in control arm (Demirol
2004; Aghahosseini 2012; Elsetohy 2015; El-Toukhy 2016; Smit
2016; Alleyassin 2017). In one trial, investigators performed an
endometrial biopsy of suspicious lesions after injecting methylene
blue in the hysteroscopy arm, while no intervention was done in
the control arm (Shawki 2012).
In six trials, investigators performed a hysteroscopy and treated
all of the detected intracavitary abnormalities prior to IVF in the
intervention arm (Demirol 2004; Rama Raju 2006; El-Nashar
2011; Shawki 2012; Elsetohy 2015; Alleyassin 2017). In two tri-
als, some of the intracavitary abnormalities detected during hys-
teroscopy were treated in the intervention arm, while some were
not treated (El-Toukhy 2016; Smit 2016). In two trials, it was not
clear if detected abnormalities were treated (Aghahosseini 2012;
Juul Hare 2018).
Outcomes
Seyam 2015 did not report the primary outcome of live birth; the
study report indicated the assessment of the cumulative ongoing
pregnancy rate, although ongoing pregnancy was not defined. We
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used the data for this outcome as a surrogate for live birth. This
study assessed an outcome measure - patient compliance - which
was not of interest to this Cochrane Review.
Among the IVF population, six trials reported the primary out-
come of live birth (Rama Raju 2006; Aghahosseini 2012; Elsetohy
2015; El-Toukhy 2016; Smit 2016; Juul Hare 2018). Four trials
reported the primary outcome of adverse events (Elsetohy 2015;
El-Toukhy 2016; Smit 2016; Juul Hare 2018). All ten trials re-
ported clinical pregnancy rate as an outcome.
Excluded studies
We excluded three trials for not addressing the research questions
of interest for the randomised comparisons in subfertile women
wishing to conceive spontaneously or before IUI (Brown 2000;
El-Khayat 2015; Shokeir 2016). See ’Characteristics of excluded
studies’ tables.
Among the IVF population, we excluded seven trials in ten records
(Fatemi 2010; Wang 2011; Kasius 2013; Kamel 2015; Zhang
2015; Hebeisha 2018; Siristatidis 2017). Two trials were non-ran-
domised, and hence, excluded (Kamel 2015; Siristatidis 2017).
One was a prevalence study (Fatemi 2010), and another was a
cost analysis study (Kasius 2013). One study was excluded due
to a different study population (women with endometritis (Wang
2011)), and another study was excluded because hysteroscopy was
performed in both the intervention and control arms, and those
with intracavitary abnormalities were excluded (Zhang 2015). In
another trial, the investigators mainly evaluated the role of en-
dometrial scratch before Intracytoplasmic sperm injection (ICSI),
and excluded women who were found to have intracavitary ab-
normalities during hysteroscopy (Hebeisha 2018).
Risk of bias in included studies
We assessed the included studies for methodological quality using
the Cochrane ’Risk of bias’ tool (Higgins 2011). See the ’Risk of
bias’ graph (Figure 2), and ’Risk of bias’ summary (Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Generation of random sequence
Eight studies used adequate methods for random sequence gener-
ation and were at low risk of selection bias (Demirol 2004; Rama
Raju 2006; Shawki 2012; Elsetohy 2015; El-Toukhy 2016; Smit
2016; Alleyassin 2017; Juul Hare 2018). Two multicentre trials
among these seven studies used an intended third party trial man-
agement system (El-Toukhy 2016), and web-based randomisa-
tion (Smit 2016). The remaining three studies did not report the
method used for randomisation clearly, and we categorised them
as unclear risk of bias (El-Nashar 2011; Aghahosseini 2012; Seyam
2015).
Allocation concealment
Only two studies clearly stated the method of allocation conceal-
ment and we rated them at low risk of bias (El-Toukhy 2016;
Smit 2016). The remaining nine trials did not state the method
of allocation concealment clearly, and we assessed them as unclear
risk of bias (Demirol 2004; Rama Raju 2006; El-Nashar 2011;
Aghahosseini 2012; Shawki 2012; Elsetohy 2015; Seyam 2015;
Alleyassin 2017; Juul Hare 2018).
Blinding
Most of the studies did not report blinding of either clinician or
participant. One study mentioned blinding of clinician and em-
bryologist (Alleyassin 2017), and one study mentioned blinding
of embryologist and researcher for allocated group (El-Toukhy
2016). Since the outcomes (live birth, complications following
hysteroscopy, ongoing and clinical pregnancy) were objective, we
did not downgrade the quality of the studies for lack of blinding.
Further, It was unlikely that the hysteroscopies were not performed
according to the required standards, due to a lack of blinding. For
these stated reasons, we deemed all the included studies to be at
low risk of this bias.
Incomplete outcome data
Seven studies were deemed to be at low risk of attrition bias
(Demirol 2004; Shawki 2012; Elsetohy 2015; Seyam 2015;
El-Toukhy 2016; Smit 2016; Juul Hare 2018). Four studies did
not mention about dropouts, and not enough information was
available to make a judgement, hence, we deemed them as un-
clear risk of bias (Rama Raju 2006; El-Nashar 2011; Aghahosseini
2012; Alleyassin 2017).
Selective reporting
We judged Seyam 2015 to be at high risk of selective outcome
reporting (live birth, primary outcome of interest not reported,
even though study duration was long enough (seven years), giving
sufficient time for authors to capture live birth data). We judged
six trials evaluating women undergoing IVF at low risk of bias for
selective reporting (RamaRaju 2006; Aghahosseini 2012; Elsetohy
2015; El-Toukhy 2016; Smit 2016; Juul Hare 2018), and four
trials as unclear risk of bias, since live birth was not reported (
Demirol 2004; El-Nashar 2011; Shawki 2012; Alleyassin 2017).
Other potential sources of bias
Two trials, published as conference abstracts, did not have
enough information available for us to judge, hence, we deemed
both of these studies as unclear risk of bias (El-Nashar 2011;
Aghahosseini 2012). One of these trials had an uneven distribu-
tion of randomised participants (142 versus 211), with substan-
tially higher control numbers, with no clear available explanation
(Aghahosseini 2012). We deemed another trial, which was also
only available as a conference abstract, as high risk for this do-
main, due to premature termination of the trial. The authors made
the decision due to slow recruitment (Juul Hare 2018). We did
not observe any potential source of bias in the remaining eight
trials, and deemed them to be at low risk (Demirol 2004; Rama
Raju 2006; Shawki 2012; Elsetohy 2015; Seyam 2015; El-Toukhy
2016; Smit 2016; Alleyassin 2017).
Effects of interventions
See: Summary of findings for the main comparison Screening
hysteroscopy versus no hysteroscopy in women wishing to
conceive spontaneously; Summary of findings 2 Screening
hysteroscopy versus no hysteroscopy in women before IVF
1. A routine screening hysteroscopy, including
hysteroscopic treatment of any detected uterine
cavity abnormalities, versus no hysteroscopy, in
subfertile women wishing to conceive spontaneously
Primary outcomes
1.1 Live birth rate
Seyam 2015 reported data on ongoing pregnancies: we used these
data as a surrogate outcome for the primary outcome of effective-
ness, the live birth rate. There is very low-quality evidence, and we
are uncertain whether ongoing pregnancy rate improves following
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screening hysteroscopy in women with at least two years of unex-
plained subfertility compared to no hysteroscopy (risk ratio (RR)
4.30, 95% confidence interval (CI) 2.29 to 8.07; 1 RCT; partici-
pants = 200; Analysis 1.1; Figure 4). If 10% of women achieve an
ongoing pregnancy without hysteroscopy, the evidence suggests
that 43% of women (95% CI 23% to 81%) will achieve an on-
going pregnancy after hysteroscopy.
Figure 4. Forest plot of comparison 1. Screening hysteroscopy versus no hysteroscopy in subfertile women.
Outcome 1.1. Ongoing pregnancy was used as a surrogate outcome for live birth
1.2 Adverse events
Seyam 2015 reported no adverse events in either treatment arm.
The effect estimate is not estimable (Analysis 1.2).
Secondary outcomes
1.3 Clinical pregnancy rate
There is very low-quality evidence, and we are uncertain whether
clinical pregnancy rate improves following screening hysteroscopy
in women with at least two years of unexplained subfertility com-
pared to no hysteroscopy (RR 3.80, 95% CI 2.31 to 6.24; 1 RCT;
participants = 200; Analysis 1.3). If 15% of women achieve a clin-
ical pregnancy without hysteroscopy, the evidence suggests that
57% of women (95% CI 35% to 94%) will achieve an clinical
pregnancy after hysteroscopy.
1.4 Miscarriage rate
There is very low-quality evidence, and we are uncertain whether
miscarriage rate increases following screening hysteroscopy com-
pared to no hysteroscopy in women with at least two years of unex-
plained subfertility compared to no hysteroscopy (RR 2.80, 95%
CI 1.05 to 7.48; 1 RCT; participants = 200; Analysis 1.4).
Sensitivity analyses
Sensitivity analyses on the choice of the summary effect measure
(OR versus RR versus RD) or the analysis model (random-effects
versus fixed-effect model) did not demonstrate differences of the
direction of the treatment effect or the statistical significance tests
for the outcomes live birth and clinical pregnancy.
2. Hysteroscopy versus no hysteroscopy for subfertile
women undergoing intrauterine insemination (IUI)
We found no trials that investigated this comparison.
3. A routine screening hysteroscopy, including
hysteroscopic treatment of any detected uterine
cavity abnormalities, versus no hysteroscopy before in
vitro fertilisation (IVF)
We pooled results from ten trials (3750 women) for this com-
parison (Demirol 2004; Rama Raju 2006; El-Nashar 2011;
Aghahosseini 2012; Shawki 2012; Elsetohy 2015; El-Toukhy
2016; Smit 2016; Alleyassin 2017). Investigators of three trials
reported performing endometrial biopsy along with hysteroscopy
in the intervention arm (Rama Raju 2006; El-Nashar 2011; Juul
Hare 2018).
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Primary outcomes
3.1 Live birth rate
Six trials reported live birth rate. Low quality-evidence indicates
that performing screening hysteroscopy before IVF may increase
live birth rate compared to no hysteroscopy (RR 1.26, 95% CI
1.11 to 1.43; 6 RCTs; participants = 2745, I² = 69%; Analysis 2.1;
Figure 5). For a typical clinic with 22% live birth rate, performing
a screening hysteroscopy would be expected to result in live birth
rates between 25% and 32%.
Figure 5. Forest plot of comparison 2. Screening hysteroscopy versus no hysteroscopy in women under IVF.
Outcome 2.1. Live birth.
Sensitivity analysis
We performed sensitivity analysis, and after removing two trials
in which an additional procedure (endometrial biopsy) was per-
formed along with hysteroscopy, the result did not change (Rama
Raju 2006; Juul Hare 2018): there was an increase in live birth
rate in the intervention group (RR 1.19, 95% CI 1.03 to 1.37;
4 RCTs; participants = 2008; I² = 77%). When we removed four
trials with unclear or high risk for bias for any domain (Rama
Raju 2006; Aghahosseini 2012; Elsetohy 2015; Juul Hare 2018),
the pooled result showed no increase in live birth rate following
screening hysteroscopy (RR 0.99, 95% CI 0.82 to 1.18; 2 RCTs;
participants = 1452; I² = 0%). Sensitivity analyses on the choice
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of the summary effect measure (OR versus RR ), or the analysis
model (fixed-effect versus random-effects model) did not demon-
strate differences in the direction of the treatment effect, or the
statistical significance tests.
Subgroup analysis
We conducted a priori subgroup analyses based on the number
of IVF attempts for: an unselected IVF population, before first
IVF attempt, and after two or more IVF failures. It showed no
evidence of a difference between the subgroups; test for subgroup
differences: Chi² = 0.35, df = 2 (P = 0.84), I² = 0%.
3.1.1 Live birth rate in unselected population
There was no evidence of a difference in live birth rate following
screening hysteroscopy versus no hysteroscopy in an unselected
IVF population (RR 1.23, 95% CI 0.63 to 2.40; 1 RCT; partici-
pants = 217; I² = not applicable; Analysis 2.1; Figure 5).
3.1.2 Live birth rate before first IVF
There was no evidence of a difference in live birth rate following
screening hysteroscopy versus no hysteroscopy in women under-
going their first IVF (RR 1.20, 95% CI 0.96 to 1.49; 2 RCTs;
participants = 953; I² = 86%; Analysis 2.1; Figure 5).
2.1.3 Live birth rate after two or more IVF failures
There was an increase in live birth rate following screening hys-
teroscopy versus no hysteroscopy in women with two or more IVF
failures (RR 1.30, 95% CI 1.10 to 1.53; 3 RCTs; participants =
652; I² = 78%; Analysis 2.1; Figure 5).
3.2 Adverse events
Four trials reported adverse events. Three trials did not report any
adverse events following hysteroscopy (Elsetohy 2015; El-Toukhy
2016; Juul Hare 2018). One trial reported a case of endometritis
in the hysteroscopy arm (Smit 2016). There is very low-quality
evidence, and we are uncertain whether screening hysteroscopy
is associated with higher adverse events versus no hysteroscopy
(Peto odds ratio (OR) 7.47, 95% CI 0.15 to 376.42; 4 RCTs;
participants = 1872; I² = not applicable; Analysis 2.2).
Secondary outcomes
3.3 Clinical pregnancy rate
Ten trials reported clinical pregnancy rate. Low-quality evidence
indicates that performing screening hysteroscopy before IVF may
increase clinical pregnancy rate compared to no hysteroscopy (RR
1.32, 95% CI 1.20 to 1.45; 10 RCTs; participants = 3750; I² =
49%; Analysis 2.3; Figure 6). For a typical clinic with 28% clinical
pregnancy rate, performing a screening hysteroscopy would be
expected to result in clinical pregnancy rates between 33% and
40%.
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Figure 6. Forest plot of comparison 2. Screening hysteroscopy versus no hysteroscopy in women under IVF.
Outcome 2.3. Clinical pregnancy
Sensitivity analysis
We conducted a sensitivity analysis by removing eight trials with
unclear or high risk for bias for any domain (Demirol 2004;
Rama Raju 2006; El-Nashar 2011; Aghahosseini 2012; Shawki
2012; Elsetohy 2015; Alleyassin 2017; Juul Hare 2018), which
showed no increase in clinical pregnancy rate following screening
hysteroscopy (RR1.03, 95%CI 0.87 to 1.21; 2RCTs; participants
= 1452; I² = 0%). Sensitivity analyses on the choice of the summary
effect measure (OR versus RR ), or the analysis model (fixed-effect
versus random-effects model), did not demonstrate differences in
the direction of the treatment effect, or the statistical significance
tests.
Subgroup analysis
We conducted subgroup analysis according to the number of IVF
attempts. It showed no evidence of a difference between the sub-
groups: test for subgroup differences: Chi² = 1.96, df = 2 (P =
0.38), I² = 0%.
2.3.1 Clinical pregnancy rate in unselected IVF population
There was an increase in clinical pregnancy rate following screen-
ing hysteroscopy in an unselected IVF population (RR 1.40, 95%
CI 1.07 to 1.84; 3 RCTs; participants = 581; I² = 0%; Analysis
2.3; Figure 6).
2.3.2 Clinical pregnancy rate before first IVF
There was an increase in clinical pregnancy rate following screen-
ing hysteroscopy before first IVF (RR 1.20, 95% CI 1.02 to 1.41;
3 RCTs; participants = 1173; I² = 63%; Analysis 2.3; Figure 6).
2.3.3 Clinical pregnancy rate after two or more IVF failures
There was an increase in clinical pregnancy rate following screen-
ing hysteroscopy in women with two or more IVF failures (RR
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1.37, 95% CI 1.21 to 1.56; 4 RCTs; participants = 1996; I² =
72%; Analysis 2.3; Figure 6).
3.4 Miscarriage rate per woman randomised
Three trials reported miscarriage rate. Low-quality evidence in-
dicates that there may be little or no difference in miscarriage
rate following screening hysteroscopy versus no hysteroscopy (RR
1.01, 95% CI 0.67 to 1.50; 3 RCTs; participants = 1669; I² = 0%;
Analysis 2.4). There may be little or no difference in miscarriage
rate per pregnancy between the two groups (RR 0.97, 95% CI
0.67 to 1.40).
Subgroup analysis, according to the number of IVF attempts,
showed no evidence of a difference between the subgroups; test
for subgroup differences: Chi² = 1.07, df = 2 (P = 0.59), I² = 0%.
In the subgroup analysis, there was one trial each under unselected
population, first IVF, and two or more IVF failures, and we noted
little or difference between the miscarriage rate between the two
groups.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Screening hysteroscopy versus no hysteroscopy in women before IVF
Patient or population: women before IVF treatment
Setting: academic and private clinics
Intervention: screening hysteroscopy
Comparison: no hysteroscopy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no hys-
teroscopy
Risk with hysteroscopy
Live birth 221 per 1000 279 per 1000
(245 to 316)
RR 1.26
(1.11 to 1.43)
2745
(6 RCTs)
⊕⊕©©
lowa,b
Adverse events 0 per 1000 0 per 1000
(0 to 0)
Peto OR 7.47
(0.15 to 376.42)
1872
(4 RCTs)
⊕⊕©©
very lowa,c
Clinical pregnancy 278 per 1000 368 per 1000
(334 to 404)
RR 1.32
(1.20 to 1.45)
3750
(10 RCTs)
⊕⊕©©
lowa,d
Miscarriage 53 per 1000 53 per 1000
(35 to 79)
RR 1.01
(0.67 to 1.50)
1669
(3 RCTs)
⊕⊕©©
lowa,e
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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aSerious risk of bias, downgraded by one level: only two studies had low risk of bias for all the domains. The rest of the
studies had unclear risk for allocat ion concealment. One study was categorised at high risk for ’other’ domain. There is a
likely chance of overest imating the treatment.
bSerious inconsistency, downgraded by one level: there is a stat ist ical heterogeneity of 69%, which is substant ial.
cVery serious risk of imprecision, downgraded by two levels: due to wide conf idence interval; number of events is too low.
dSerious inconsistency, downgraded by one level: there is a stat ist ical heterogeneity of 49%, which is moderate.
eSerious risk of imprecision, downgraded by one level: due to wide conf idence interval.
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D I S C U S S I O N
Summary of main results
Screening hysteroscopy versus no hysteroscopy in subfertile
women wishing to conceive spontaneously
We retrieved only one single-centre study, which reported ongoing
pregnancy as a surrogate outcome for live birth. There was very
low-quality evidence, and we are uncertain whether a screening
hysteroscopy improves the ongoing or clinical pregnancy rates in
women with at least two years of unexplained subfertility com-
pared to no hysteroscopy (Summary of findings for the main
comparison). The included trial reported no adverse events (com-
plications following hysteroscopy) in either comparison arm. Evi-
dence was very low-quality, and we are uncertain whether screen-
ing hysteroscopy increases miscarriage rate compared to no hys-
teroscopy.
Screening hysteroscopy versus no hysteroscopy before
intrauterine insemination (IUI)
We found no studies that investigated this comparison.
Sreening hysteroscopy versus no hysteroscopy before in
vitro fertilisation (IVF)
There was low-quality evidence that indicates that performing a
screening hysteroscopy before IVF may increase the live birth and
clinical pregnancy rates compared to no hysteroscopy (Summary
of findings 2). Sensitivity analysis performed by excluding those
studies in which hysteroscopy was combined with endometrial
biopsy, showed similar estimates for live birth and clinical preg-
nancy rates between the two groups. Importantly, sensitivity anal-
ysis done by pooling only trials with low risk of bias showed no
improvement in live birth and clinical pregnancy rates following
screening hysteroscopy. With very low-quality evidence, we are
uncertainwhether screening hysteroscopy is associatedwith higher
adverse events (complications related to hysteroscopy) versus no
hysteroscopy. Low-quality evidence indicates little or no differ-
ence in miscarriage rate following screening hysteroscopy versus
no hysteroscopy.
Overall completeness and applicability of
evidence
At present, there is no high-quality evidence to support the routine
use of hysteroscopy as a screening tool in the general subfertile
population, for improving reproductive outcomes. We retrieved
only one trial, that provided very low-quality evidence, and as-
sessed the effects of screening hysteroscopy in women with unex-
plained subfertility trying to conceive spontaneously.
The current review suggests that screening hysteroscopy may in-
crease live birth and clinical pregnancy rates compared to no inter-
vention, in women undergoing IVF. However, the applicability of
the evidence may have some limitations and may vary according
to different subpopulations. The subgroup analysis suggests that
screening hysteroscopy may benefit women with two or more IVF
failures.
We observed the presence of variations in eligibility criteria among
individual trials in terms of additional radiological procedures
done (e.g. hysterosalpingogram (HSG)) before 2Dultrasound ver-
sus only 2D ultrasound, hysteroscopy naive versus previous his-
tory of hysteroscopy, hysteroscopy alone versus hysteroscopy and
endometrial biopsy, and treatment of all detected intracavitary ab-
normalities versus selective treatment (Table 1).The literature sug-
gests that the diagnostic accuracy of 2D transvaginal ultrasound is
suboptimal in terms of detecting intrauterine pathologies, such as
polyps and adhesions, compared to other diagnostic procedures,
such as sonohysterography or hysterosalpingography (Salle 1999;
Ragni 2005). Trials including additional radiological procedures
(e.g. HSG) would screen out more women with abnormalities,
compared to trials relying solely on 2D transvaginal ultrasound be-
fore IVF, thereby, introducing some degree of heterogeneity. Fur-
ther, there is supportive evidence of benefit of endometrial scratch-
ing (a procedure similar to endometrial biopsy) before IVF, and
the addition of the same, along with screening hysteroscopy, may
influence the true estimate (Nastri 2015). There is evidence of
improved reproductive outcomes following treatment of intracav-
itary uterine abnormalities, such as a uterine septum and polyp
(Bosteels 2015; ASRM 2016). The current review included a trial
in which few women who were detected to have intracavitary ab-
normalities did not undergo correction in the intervention arm,
and this could be a possible source of heterogeneity (Table 1).
There could be some clinical heterogeneity among studies due to
these stated variations in trials’ protocols, as well as inclusion and
exclusion criteria for recruited participants. In the IVFpopulation,
due to the high statistical heterogeneity for outcomes, such as live
birth (69%) and clinical pregnancy (49%), these results should be
interpreted with caution.
The optimum timing to perform hysteroscopy is still not clear,
since the time interval between screening hysteroscopy and IVF
varied between one and three months, although most included
studies performed the hysteroscopy in the preceding menstrual
cycle. Further, since the review included only studies involving
fresh IVF cycles, the evidence cannot be extrapolated to other
types of ART treatments, such as frozen cycles. Importantly, the
complications associated with hysteroscopy were reported by very
few studies.
Quality of the evidence
The current review had three comparisons
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• Hysteroscopy versus no hysteroscopy for subfertile women
wishing to conceive spontaneously
• Hysteroscopy versus non hysteroscopy for subfertile women
undergoing IUI.
• Hysteroscopy versus no hysteroscopy for women
undergoing IVF.
In the comparison for subfertile women with unexplained sub-
fertility wishing to conceive spontaneously, we reported ongoing
pregnancy (as a surrogate for live birth) rate, adverse events (com-
plications following hysteroscopy), clinical pregnancy rate, and
miscarriage rate. The quality of the evidence was very low for the
outcomes ongoing pregnancy and clinical pregnancy rates. Only
one trial was included, and we downgraded by two levels for risk
of bias and one level for indirectness. We assessed the evidence to
be very low-quality for miscarriage rate, downgrading by one level
each for risk of bias, indirectness, and imprecision.
We did not find any trials that compared screening hysteroscopy
versus no hysteroscopy before IUI.
For the comparison with the greatest number of studies, i.e. study-
ing an IVF population, we reported on live birth, adverse events
(complications following hysteroscopy), clinical pregnancy rate,
and miscarriage rate. Overall, the evidence for live birth and clin-
ical pregnancy was of low quality. We found the majority of the
studieswith unclear descriptions of allocation concealment, hence,
we downgraded by one level for risk of bias. We found substantial
statistical heterogeneity (49% to 69%), which could not be ex-
plained on the basis of differences in population or intervention,
hence, we downgraded the evidence by a further one level for the
live birth and clinical pregnancy outcomes. The adverse events out-
come, which comprised of complications following hysteroscopy,
was poorly reported, and we graded it as very low-quality evidence
(downgraded risk of bias by one, plus two levels for imprecision).
We graded the miscarriage rate outcome as low-quality evidence
due to risk of bias (downgraded by one level), and imprecision
(downgraded by one level).
Potential biases in the review process
We aimed to search for and identify all the studies eligible for this
review. The search was comprehensive, and included identifying
ongoing studies through trial registries. We also tried contacting
authors for additional information and clarification regarding their
published data. However, for conference abstracts, it was difficult
to contact authors because of the absence of contact addresses or
information. We requested clarification regarding data from nine
authors of the included studies, and got a satisfactory reply from
three authors. Additionally, two authors of this review (BWM and
FB) were investigators and authors of one of the included trials
(Smit 2016). However, both these authors did not participate in
selection of the studies or in extracting data from that study.
Agreements and disagreements with other
studies or reviews
One systematic review evaluated the role of diagnostic hys-
teroscopy in infertile couples and women undergoing IVF (Di
Spiezio Sardo 2016). For subfertile women wishing to conceive
spontaneously, the findings are in accordance with the present
Cochrane Review: there is only a limited body of evidence on the
role of hysteroscopy as a screening tool in the early assessment of
infertile women. More research is needed.
An earlier systematic review evaluated the role of office hys-
teroscopy in women undergoing IVF, and included both ran-
domised (N = 2) and non-randomised trials (N = 3 (El-Toukhy
2008)).The included studies had women who were both under-
going their first IVF, and those with two or more IVF failures. The
authors found a significant increase in clinical pregnancy following
hysteroscopy after pooling the results from both the randomised
and non-randomised trials (RR = 1.75, 95%CI 1.51 to 2.03). The
authors suggested benefit could be due to the treatment of intra-
cavitary abnormalities; negotiation of the cervical canal, thus, fa-
cilitating the subsequent embryo transfer; or inadvertent endome-
trial injury during hysteroscopy. These results are in agreement
with current review findings, where we found a possible benefit
of screening hysteroscopy, especially in women with two or more
IVF failures.
Another systematic review evaluated the role of routine hys-
teroscopy before the first IVF, and included one RCT and five
non-randomised trials (Pundir 2014). The authors reported sig-
nificantly higher clinical pregnancy rate after pooling the results
(RR, 1.44, 95%CI 1.08 to 1.92). The pooled RR for live birth was
1.30 (95%CI 1.00 to 1.67). The authors suggested improved IVF
outcomes following routine hysteroscopy in women undergoing
their first IVF. In the subgroup population of women undergoing
their first IVF, the current review did not find an increase in live
birth or clinical pregnancy following screening hysteroscopy. The
reason for the difference from the earlier review could be due to
the inclusion of non-randomised trials, which often overestimate
the treatment effect.
In a fourth systematic review, the authors pooled three trials un-
der the diagnostic hysteroscopy group, and found increased live
birth following hysteroscopy compared to control (RR1.48, 95%
CI 1.20 to 1.81); the quality of the evidence was very low. The
pooled results from seven trials, found an increase in clinical preg-
nancy following hysteroscopy (RR 1.45, 95% CI 1.26 to 1.67);
the quality of the evidence was moderate (Di Spiezio Sardo 2016).
The current review pooled results from an additional three trials
(Smit 2016; Alleyassin 2017; Juul Hare 2018). However, the re-
sults from both these reviews are in broad agreement.
A U T H O R S ’ C O N C L U S I O N S
24Screening hysteroscopy in subfertile women and women undergoing assisted reproduction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for practice
At present, there is no high-quality evidence to support the routine
use of hysteroscopy as a screening tool in the general population
of subfertile women with a normal ultrasound or hysterosalpin-
gogram in the basic fertility work-up to improve reproductive suc-
cess rates.
In women undergoing in vitro fertilisation (IVF), low-quality ev-
idence from all studies reporting these outcomes, suggests that
performing a screening hysteroscopy before IVF may increase live
birth and clinical pregnancy rates. However, pooled results from
the only two trials at low risk of bias, did not show that a screen-
ing hysteroscopy before IVF provided any benefit. Since the stud-
ies showing an effect are those with unclear allocation conceal-
ment, we are uncertain whether a routine screening hysteroscopy
increases live birth and clinical pregnancy, be it for all women or
those with two or more failed IVF attempts. There is insufficient
evidence to draw conclusions about the safety of screening hys-
teroscopy.
Implications for research
High-quality randomised controlled trials are needed to assess the
effectiveness of hysteroscopy as a screening tool in the general
population of women with fertility problems, whether planning
to conceive spontaneously, or undergo IUI or IVF. . Future trials
should also assess the cost-effectiveness of hysteroscopy as a screen-
ing tool in both these populations.
Even after publication of large, adequately powered trials evalu-
ating the role of screening hysteroscopy before IVF, the uncer-
tainties about its role seem to persists. Indeed, if there is a possi-
ble beneficial effect of screening hysteroscopy, the mechanism is
not clear. There is a need to conduct trials comparing therapeu-
tic intervention for intra cavitary abnormalities detected during
screening hysteroscopy versus no intervention, and screening hys-
teroscopy versus sham procedure, involving only cervical dilation,
before IVF, which will help elucidate the mechanism and explore
its true effect. Trials are also needed to explore the optimal timing
of a screening hysteroscopy before IVF. It remains uncertain if hys-
teroscopy alone, or hysteroscopy along with endometrial biopsy
or scratching is beneficial. There is also a need to evaluate whether
inclusion of women who are hysteroscopy naive versus those with
a history of previous hysteroscopy, impact the outcomes.
Future trials should also report live birth or ongoing clinical preg-
nancy rate as an outcome. Pain, discomfort, and procedural com-
plications associated the hysteroscopy should be adequately re-
ported as outcomes in the trials.
Recent years have seen an increasing interest in basic research into
the complex molecular network of the implantation process of the
human embryo. This has led to the identification of markers of
endometrial receptivity to help improve the clinical outcomes of
IVF. The comparative cost-effectiveness of screening hysteroscopy
versus the use of markers of endometrial receptivity is needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aghahosseini 2012
Methods RCT
Single centre
Iran
Participants Inclusion:
women undergoing IVF with at least two implantation failures (recurrent ART failure)
younger than 38 years, BMI less than 35 kg/m², no hysteroscopy in 2 months, normal
HSG
Exclusion:
not mentioned
Interventions Intervention group (N = 142) underwent hysteroscopy prior to ART. Nomention of any
additional procedures during hysteroscopy, or whether abnormalities found were treated
Control group (N = 211) did not undergo hysteroscopy.
Outcomes Clinical pregnancy rate, live birth rate, abnormal and normal hysteroscopy findings
Notes This was published as a conference abstract. Authors did not respond to emails for
clarification regarding participants and data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors use ’randomized’ in the abstract. However, informa-
tion provided was insufficient for making a judgement
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence performance bias. Hence, absence
of blinding was categorized as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence the findings for our primary and sec-
ondary outcomes, hence, categorised as low risk for detection
bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided regarding losses to follow-up or
dropouts
Insufficient information for making a judgement
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Aghahosseini 2012 (Continued)
Selective reporting (reporting bias) Low risk No published protocol. However, all the prespecified out-
comes of interest (including live birth) were reported
Other bias Unclear risk The numbers randomised in both groups were uneven (142 vs
211) and control groupnumberswere substantially higher.No
clear explanation was available for the unbalanced numbers
since this is a conference abstract and authors did not respond
to emails for clarification
Alleyassin 2017
Methods RCT
Single centre
Iran
Participants Inclusion:
women undergoing first ICSI treatment
normal TVS scan and normal HSG
Exclusion:
women with recurrent miscarriages
undergone hysteroscopy earlier
Interventions Intervention group (N=110): hysteroscopy done;mid-luteal phase and down, regulation
done using buserelin; rigid hysteroscopy was used, vaginoscopic approach
Intracavitary uterine abnormalities noticedwere treated in the same sitting.No additional
procedure, such as endometrial biopsy, were mentioned
Control group (N =110): no hysteroscopy before ICSI treatment
Outcomes Clinical pregnancy rate, miscarriage rate, multiple pregnancy rate, normal and abnormal
hysteroscopy findings
Notes Authors were contacted for data, however, authors did not respond to emails
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated table of random numbers”.
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The physician performing embryo transfer and embryologist
were blinded for group allocation.”
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Alleyassin 2017 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk While physician performing embryo transfer and embryolo-
gist were blinded, it was not clear if outcome assessors were
blinded.However, blindingwas unlikely to influence the find-
ings for our primary and secondary outcomes, hence, cate-
gorised as low risk for detection bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk While all the randomised participants were included in the
analysis, no dropouts were mentioned
Selective reporting (reporting bias) Unclear risk The published protocol for this study was not available.While
prespecified outcomes were reported, primary outcome (live
birth) was not reported
Other bias Low risk We found no other potential sources of within-study bias.
Source of funding was not mentioned
Demirol 2004
Methods RCT
Single centre
Turkey
Participants Women who had undergone two or more failed IVF cycles, in which two or more good
quality embryos were transferred
All the participants had normal HSG (normal intrauterine cavity and bilaterally patent
tubes)
Age group 24 to 40 years
All women had primary infertility
Interventions Intervention group (N = 210) had office hysteroscopic evaluation of uterine cavity and
cervix with intrauterine lesions treated during the office procedure. No additional pro-
cedure, such as endometrial biopsy, was mentioned
Hysteroscopy was performed in the early proliferative phase, using saline distension
medium
All office hysteroscopies were performed 2 to 6 months after the last failed IVF cycle, by
the same physician
All IVF treatments were carried out on the menstrual cycles after office hysteroscopy
Control group (N = 211) did not have hysteroscopy prior to IVF
Outcomes Clinical pregnancy rate, first trimester miscarriage rate, normal and abnormal hys-
teroscopy findings
Notes Authors were contacted for clarification regarding data, however authors did not respond
to emails
Risk of bias
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Demirol 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized into two groups using computer generated
random numbers”
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blindingwas notmentioned.However, absence of blinding
was unlikely to influence performance bias.Hence, absence
of blinding was categorised as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned.However, absence of blinding
is unlikely to influence the findings for our primary and
secondary outcomes, hence categorized under “ low risk”
for detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to follow-up were
mentioned and appeared to be balanced.
Intention-to-treat analysis was done.
Selective reporting (reporting bias) Unclear risk The published protocol for this study was not available.
While the
prespecified outcomes were reported, the primary outcome
(live birth) was not reported
Other bias Low risk We found no other potential sources of within-study bias.
Instituitional ethical board clearance and source of funding
was not mentioned
El-Nashar 2011
Methods RCT
Single centre
Egypt
Participants Included women with primary infertility undergoing ICSI cycle; no other criteria men-
tioned
Exclusion criteria: not mentioned
Interventions Intervention group (N = 62) underwent hysteroscopy and directed endometrial biopsy
before ICSI. Any uterine abnormalities found were corrected
Control group (N = 62): no hysteroscopy
Outcomes Clinical pregnancy rate, normal and abnormal hysteroscopy findings
Notes This was published as a conference abstract. There was no response from authors to
email queries regarding participants and data
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El-Nashar 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors use “randomized” in the abstract. However, infor-
mation provided was insufficient for making a judgement
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence performance bias. Hence, absence
of blinding was categorised as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence the findings for our primary and
secondary outcomes, hence, categorised as low risk for de-
tection bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided regarding losses to follow-up or
dropouts. Insufficient information for making a judgement
Selective reporting (reporting bias) Unclear risk No published protocol. While all the prespecified outcomes
were reported, primary outcome (live birth) was not re-
ported
Other bias Unclear risk There was not enough information to make a judgement.
This was a conference abstract
El-Toukhy 2016
Methods RCT
Multicenter
European centres
Participants Included women aged < 38 years who had undergone at least two, three, or four fresh
IVF or frozen cycles without a pregnancy
Normal ultrasound assessment of the uterine cavity
At least 8 oocytes retrieved in the previous IVF cycle
Exclusion
Less than two, or more than four failed IVF cycles ending in an embryo transfer
Hysteroscopy less than two months before randomisation
Submucous or intramural fibroids diagnosed by ultrasound found to be distorting the
uterine cavity
Untreated tubal hydrosalpinges
BMI > 35 kg/m²
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El-Toukhy 2016 (Continued)
Interventions Intervention group (N = 350 ) had outpatient hysteroscopy.
Hysteroscopy was performed in the early proliferative phase using saline distension
medium. intracavitary abnormalities, such as endometrial polyps, septums, and submu-
cosal fibroids were treated
No additional procedure, such as endometrial biopsy, was done
All IVF treatments were carried out on the menstrual cycles after office hysteroscopy
Control group (N = 352 ) had no hysteroscopy.
Outcomes Live birth rate, positive pregnancy rate, clinical pregnancy rate, implantation rate, mis-
carriage rate, normal and abnormal findings of hysteroscopy, adverse events following
hysteroscopy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly assigned using independent third
party trial management system”
Allocation concealment (selection bias) Low risk “Allocation concealment was done to mask the
researchers to the order of group assignment at
randomisation and recruitment”. The minimisa-
tion procedure, with a computer-based algorithm
from the integrated trial management system, in-
corporates allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk While the embryologists were not aware of the al-
located group, the physicians performing the em-
bryo transfer were not blinded. However, absence
of blindingwas unlikely to influence performance
bias. Hence, absence of blinding was categorised
as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The researchers were not aware of the allocated
group. Secondary outcome assessors and physi-
cians were not blinded. Further, absence of blind-
ing was unlikely to influence the findings for our
primary and secondary outcomes, hence, cate-
gorised as low risk for detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to follow-
up were mentioned and appeared to be balanced.
Intention-to-treat analysis was done.
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El-Toukhy 2016 (Continued)
Selective reporting (reporting bias) Low risk Published protocol was available. All the prespeci-
fied outcomes (including live birth) were reported
in the final analysis
Other bias Low risk We found no other potential sources of within-
study bias. Details regarding source of funding
and ethical clearance were mentioned
Elsetohy 2015
Methods RCT
Egypt
Single centre
Participants Included women undergoing first IVF/ICSI treatment
Normal transvaginal ultrasound apart from intramural myomas without uterine cavity
deformity
HSG done in the past one year
Exclusion criteria:
Uterine factor infertility
History of recurrent miscarriage
Abnormal HSG
Abnormal transvaginal ultrasound
Previous uterine surgery
Contraindication for hysteroscopy
Interventions Intervention group (N = 102) had office hysteroscopic evaluation of uterine cavity and
cervix; intrauterine lesions treated during the office procedure
Hysteroscopy was performed in the early mid-follicular phase of a menstrual cycle (day 3
to12) with a vaginoscopic approach without anaesthesia, using saline infusion medium
No additional procedure, such as endometrial biopsy, was done
All IVF/ ICSI treatments were carried out within three months of hysteroscopic exami-
nation
Control group (N = 101) had no hysteroscopy.
Outcomes Clinical pregnancy rate
Live birth rate
Adverse events
Notes Authors were contacted for clarification regarding data (clinical pregnancy rate) and
response recorded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a computer generated table of random numbers”
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Elsetohy 2015 (Continued)
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence performance bias. Hence, absence
of blinding was categorised as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence the findings for our primary and
secondary outcomes, hence, categorised as low risk for de-
tection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to follow-up were
mentioned, and appeared to be balanced.
However, intention-to-treat analysis not done.
Selective reporting (reporting bias) Low risk The published protocol for this study was not available,
however,
prespecified outcomes of interest (including live birth) were
reported
Other bias Low risk We found no other potential sources of within-study bias.
Source of funding was not mentioned
Juul Hare 2018
Methods Randomized controlled trial
Denmark
Two centres
Participants Inclusion criteria:
Age: 18 to 40 years
Women submitted to IVF or ISCI treatment with previous one IVF failure (before 2nd
IVF cycle)
• Age > 18 years
• Women able to read, speak, and understand Danish
• Written consent
Exclusion Criteria:
• Intrauterine abnormalities
• Infection
• BMI > 35
• Known intrauterine cause to the infertile condition
• Abuse of alcohol or drugs
• Untreated medical condition
• Pregnancy
Interventions Intervention: hysteroscopy with endometrial biopsy (N = 112) before 2nd IVF cycle
Control: no hysteroscopy (N = 105)
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Juul Hare 2018 (Continued)
Outcomes Clinical pregnancy, miscarriage rate, live birth rate, complication rates
Notes This was published as a conference abstract. The authors were contacted through email;
authors responded and gave clarification regarding data and methods used in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a computer generated randomiza-
tion”, as stated by authors
Allocation concealment (selection bias) Unclear risk Author responded “computer randomiza-
tion and SAS program”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not done. However, absence
of blinding was unlikely to influence per-
formance bias. Hence, absence of blinding
was categorised as low risk for performance
bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not done. However, absence
of blinding was unlikely to influence the
findings for our primary and secondary
outcomes, hence, categorised as low risk for
detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to
follow-up were mentioned.
Intention-to-treat analysis was done.
Selective reporting (reporting bias) Low risk Published protocol was available. All
the prespecified outcomes (including live
birth) were reported in the final analysis
Other bias High risk Original sample size for the trial was 300.
However, the trial was stopped prematurely
due to slow recruitment
Rama Raju 2006
Methods RCT
Single centre
India
Participants Included women who had undergone two or more failed IVF cycles, in which two or
more good quality embryos were transferred per procedure
Normal HSG (normal intrauterine cavity)
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Rama Raju 2006 (Continued)
Informed consent obtained before study entry
Patient aged between 26 and 30 years
All patients had primary infertility
No exclusion criteria mentioned
Interventions Intervention group (N = 255) had outpatient hysteroscopy and sampling of the en-
dometrium for histological evaluation (endometrial biopsy)
Hysteroscopy was performed in the early proliferative phase using glycine
Abnormalities detected by hysteroscopy were corrected in the same sitting
After hysteroscopy, down regulation was initiated.
Control group (N = 265) had no hysteroscopy.
Outcomes Live birth rate, clinical pregnancy rate, miscarriage rate, abnormal and normal hys-
teroscopy findings
Notes Authors were contacted for clarification regarding data (clinical pregnancy and live birth
rate) and response recorded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized “using computer generated numbers”.
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence performance bias. Hence, absence
of blinding was categorised as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence the findings for our primary and
secondary outcomes, hence, categorised as low risk for de-
tection bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No clear information on dropouts after randomisation. It
was unclear if intention-to-treat analysis was done
Selective reporting (reporting bias) Low risk The published protocol for this study was not available, how-
ever,
prespecified outcomes of interest (including livebirth) were
reported
Other bias Low risk We found no other potential sources of within-study bias.
Source of funding was not mentioned
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Seyam 2015
Methods Parallel-group randomised controlled trial
Single centre, Arafa Hospital, Fayoum, Egypt
Protocol approved by EC/IRB: yes
Study protocol registration: not reported
Statistical power calculation: not reported
Funding: not reported
Conflicts of interest reported: no
Participants Number recruited: 200
Number randomly assigned: 200 women
Number excluded: 0 women
200 infertile women, previously diagnosed as unexplained infertility, were recruited for
the study between 2006 and 2013. All patients had a transvaginal ultrasound scanning
performed in the office prior to the procedure, to screen for uterine pathology, including
uterine anomalies, and intramural or subserosal myomas, as well as to assess uterine
position. The basic infertility work-up included a HSG to evaluate the uterine cavity
and tubal patency
Inclusion criteria:
• not reported
Exclusion criteria:
• not reported
Study duration: 84 months
Interventions Office microhysteroscopy (intervention: N = 100) vs no office microhysteroscopy
(control: N = 100)
The participants were randomised using a computer software into two groups: (A) study
group including 100 infertile women who were short-listed for the studied office micro-
hysteroscopic procedure, and (B) control group including 100 women with unexplained
infertility who were followed up without the proposed office microhysteroscopic inter-
vention
All office microhysteroscopies were performed using a malleable 0 degree diagnostic
and 30 degrees operative 2 mm fibreoptic microhysteroscope (Circon, Germany) with
an operative channel for the use of grasping forceps, scissors, or coaxial bipolar elec-
trode. Instruments were placed through the built-in operative channel when needed for
treatment of pathology, after the diagnostic portion had been completed. Typically, less
than 1 L of normal saline was used as the distention media for procedures, except with
myomectomies, which occasionally required larger volumes. Operative procedures, in-
cluding hysteroscopic resection of endometrial polyps and submucous myomas, excision
of intrauterine septum, and postoperative management plan for bicornuate uterus were
performed, where another conventional operative session for bicornuate uterus was ar-
ranged by another team. For those longer cases, fluid balance was monitored by ancillary
staff throughout the procedure. Diagnostic findings, operative outcomes, complications,
and patient tolerance during the procedure were noted. The coaxial bipolar electrode
surgical system (Versapoint, Gynecare, NJ) was used for myomectomies. Power settings
were from 60W (desiccation) to 130 W (cutting). Office microhysteroscopies were per-
formed during the early postmenstrual period. Patients received oral premedication with
midazolam (Sigma, Egypt), intramuscular analgesia with diclofenac (Epico, Egypt), and
a paracervical uterine block with 1% lidocaine (Kahira, Egypt). Five patients requested
conscious sedation with intravenous fentanyl (Cid, Egypt) and midazolam in place of
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Seyam 2015 (Continued)
the above regimen. All women were discharged immediately after the procedure, except
those who were discharged after 2 hours, due to prolonged operative indications. There
were no data on the timing of the hysteroscopy with respect to the menstrual cycle
For a 12-month follow-up period, pregnancy outcome were evaluated after the office
microhysteroscopic procedure in A and B groups, for spontaneous pregnancy without
any intervention, while each pregnancy developed after the microhysteroscopic proce-
dure was correlated to each uterine abnormality diagnosed and treated during the micro-
hysteroscopic procedure. Early pregnancy complications were evaluated for both groups,
and some of the successful ongoing pregnancies were recorded as well
Outcomes No explicit prioritisation of outcomes by the primary study authors
Main outcome: according to the abstract, the total developing cumulative spontaneous
pregnancy rate after one year of follow-up was measured. Pregnancy was not defined
in the manuscript. In the methods section, the authors mentioned that the successful
ongoing pregnancies were recorded as well. In the results section, table 2 reports data
for the cumulative pregnancy rate and the ongoing pregnancy rate. We could not obtain
further clarification from the primary study authors.
Other outcomes: patient compliance
Notes Not reported if participants had already had a hysteroscopy prior to the fertility assess-
ment or not. No information whether endometrial biopsy was performed at the time
of the screening hysteroscopy. We repeatedly contacted the corresponding author (Dr
Emaduldin Mostafa Seyam), but failed to obtain further clarification
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”The participants were randomized
using a computer software into
two groups: A. study group including 100
infertile women who were short-listed for
the studied office microhysteroscopic pro-
cedure, andB. control group including 100
women with unexplained infertility who
were followed up without the proposed of-
fice microhysteroscopic intervention”.
Comment: We could not obtain further
clarification from the primary study au-
thors on the specific computer software
used to randomise
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported - no further
clarification obtained from the primary
study authors.
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Seyam 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women were not blinded, but this did not
affect the main outcome
measures of cumulative or ongoing preg-
nancy rate. No further clarification
obtained from the primary study authors.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It was not clear who did the outcome as-
sessment. No further clarification
obtained from the primary study authors.
The main outcomes
(cumulative or ongoing pregnancy rates)
were very likely not influenced by
a lack of blinding of the outcome assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 200 women randomised - all data were
available for analysis
Selective reporting (reporting bias) High risk Protocol not available. Primary outcome
of interest not reported (live birth), even
though study duration was long enough
(seven years), giving sufficient time for au-
thors to collect live birth data
Other bias Low risk No differences in the baseline characteris-
tics. No co-treatment
Shawki 2012
Methods RCT
Single centre
Egypt
Participants Included women undergoing ICSI cycle. Mixed group consisting of women undergoing
first ICSI, or after one, two, or more failures. All women underwent HSG 2 to 3 months
prior to IVF
Exclusion:
Abnormal HSG
Abnormal TVS
Intrauterine surgery history
Contraindication for hysteroscopy
Interventions Intervention group (N = 120): vaginoscopic approach hysteroscopy done. For normal
hysteroscopy findings, methylene blue injected to identify endometrial pathology, such
as endometrial hyperplasia or endometritis, and biopsy taken. Abnormal hysteroscopy
findings were recorded and treated
Control group (N = 120): no hysteroscopy
Outcomes Implantation rate, clinical pregnancy rate, normal and abnormal hysteroscopy findings
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Shawki 2012 (Continued)
Notes Authors were contacted for data, however, authors did not respond to emails
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Containing computer generated random numbers”.
Allocation concealment (selection bias) Unclear risk Authors mention ’sealed envelopes’ containing random
numbers. Authors did not describe actual allocation con-
cealment, specifically did not mention consecutively num-
bered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence performance bias. Hence, absence
of blinding was categorised as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was not mentioned. However, absence of blinding
was unlikely to influence the findings for our primary and
secondary outcomes, hence, categorised as low risk for de-
tection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to follow-up were
mentioned, and appeared to be balanced. However, inten-
tion-to-treat analysis not done
Selective reporting (reporting bias) Unclear risk The published protocol for this study was not available.
While
prespecified outcomes of interest were reported, primary
outcome (live birth) was not reported
Other bias Low risk We found no other potential sources of within-study bias.
Source of funding was mentioned
Smit 2016
Methods RCT
Multicentre
The Netherlands
Participants Included infertile women undergoing first IVF, and normal transvaginal ultrasound
Excluded women with two or more miscarriages, intermenstrual blood loss, previously
undergone hysteroscopy
Interventions Intervention group (N = 373): hysteroscopy done; mid follicular phase, 1 to 3 months
before IVF. Uterine abnormalities noticed were treated during same sitting, or in some
cases, at subsequent sitting. No additional procedure, such as endometrial biopsy, was
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Smit 2016 (Continued)
done
Control group (N = 377): no hysteroscopy was done
Outcomes Live birth rate, ongoing pregnancy rate, implantation rate, miscarriage rate, abnormal
and normal hysteroscopy findings
Notes Authors were contacted for data, and they provided relevant data (clinical pregnancy and
live birth rate after first IVF cycle) for inclusion in the review
In a few cases in hysteroscopy group, uterine abnormalities, such as septum (n = 5), and
fibroids (n = 2), did not undergo therapeutic intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Web-based randomisation”
Allocation concealment (selection bias) Low risk Web-based randomisation incorporates allocation
concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not mentioned. However, absence
of blinding was unlikely to influence performance
bias. Hence, absence of blinding was categorised
as low risk for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Absence of blinding was unlikely to influence the
findings for our primary and secondary outcomes,
hence, categorised as low risk for detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants and losses to follow-
up were mentioned, and appeared to be balanced.
Intention-to-treat analysis was done
Selective reporting (reporting bias) Low risk Published protocol was available. All the prespeci-
fied outcomes (including live birth) were reported
in the final analysis
Other bias Low risk We found no other potential sources of within-
study bias. Details regarding source of funding
and ethical clearance were mentioned
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brown 2000 Not addressing the PICO research questions of the Cochrane Review
Parallel group randomised trial comparing the diagnostic accuracy, pain scores, and procedure length of outpatient
hysteroscopy, hysterosalpingography (HSG), and saline infusion hystero sonography (SIS) for evaluation of the
uterine cavity of infertile women
El-Khayat 2015 Not addressing the PICO research questions of the Cochrane Review
Parallel group randomised trial comparing office hysteroscopy with endometrial scratch versus office hysteroscopy
on intrauterine insemination outcome
The aim of the trial was to evaluate the role of endometrial injury in the cycle preceding ovarian stimulation for
intrauterine insemination (IUI) cycle on the clinical pregnancy rate
Fatemi 2010 Not a randomised controlled trial; prevalence study
Hebeisha 2018 Randomised trial included women undergoing IVF, and investigated role of endometrial scratch before ICSI.
The trial had three arms: first arm underwent endometrial scratch, second arm underwent hysteroscopy and
endometrial scratch, and control arm underwent direct IVF
Investigators excluded women who were found to have intracavitary abnormalities during hysteroscopy (as com-
municated by authors). Since women who had normal ultrasound but intracavitary abnormalities were excluded
from hysteroscopy, we excluded this trial, since current review focus was on effectiveness of screening hysteroscopy
with or without treatment of intracavitary abnormalities
Kamel 2015 Not a randomised controlled trial
Kasius 2013 Cost-effectiveness analysis study
Shokeir 2016 RCT on the effectiveness of local endometrial injury
To evaluate the efficacy of a hysteroscopic site-specific local endometrial injury (LEI) in a group of women with
unexplained infertility (UI), undergoing expectant management with no fertility treatment versus no intervention
Siristatidis 2017 Non randomised trial
Wang 2011 Different population; women with endometritis
Zhang 2015 Diagnostic hysteroscopy was performed for both intervention and control group to rule out intracavitary patholo-
gies. Those with intracavitary abnormalities on hysteroscopy were excluded
RCT = randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Moramezi 2012
Methods Parallel-group randomised controlled trial
Single centre, Fertility, Infertility and Perinatology Research Center, School of Medicine, Ahvaz Jundishapour Uni-
versity of Medical Sciences, Ahvaz, Iran
Protocol approved by EC/ IRB: yes
Study protocol registration: not reported
Statistical power calculation: not reported
Funding: supported by a research grant from the Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran
Conflicts of interest reported: no
Participants Number recruited: not reported
Number randomly assigned: 110 women
Number excluded: 0 women
110 healthy women, between the ages of 22 and 44 years, candidate IUI cycles, were randomly assigned to one of
two groups from the start of the cycle
Patient assessment included demographic information, as well as medical and gynaecological history taking, with
physical examination and routine laboratory screening (including BMI, CBC, PAP smear, TSH, PRL, and viral
serology)
Comment: uncertain if all women were screened by transvaginal ultrasound before entering the trial. We could not
obtain clarification from the primary study authors
Inclusion criteria:
• healthy women
Exclusion criteria:
• sexually transmitted disease
• pelvic inflammatory disease
• pregnancy
• active vaginal bleeding
Study duration: 10 months.
Interventions Hysteroscopy (intervention: N = 55) vs no hysteroscopy (control: N = 55) before IUI.
The women of group 1 (intervention, N = 55) underwent hysteroscopy to rule out pathology of the endometrial
cavity. During this procedure, the endometrial cavity was examined for the presence of polyps, or submucosal myoma,
or other pathologic conditions. Any projection inside the uterine cavity was observed, with special attention to its
shape and echo, whether it was of polypoid-like structure, or type of myomas. No data on the instrumentation used,
the timing and technique of the hysteroscopic intervention, or the type of anaesthesia
In case of surgical treatment of unsuspected uterine cavity abnormalities, IUI was started after 2 or 3 cycles, whereas
IUI was done in the next cycle when hysteroscopy was normal
The women of group 2 (control, N = 55) were treated with IUI without prior hysteroscopy
Clomifen (50 to 100 mg per day) followed by HMG (75 U per day) were given for ovarian stimulation. Transvaginal
ultrasonography was done between cycle day 12 and 14. A single dose of human chorionic gonadotrophin (hCG)
was used to induce ovulation if the follicles were about 18 to 20 mm. Semen specimens were washed using the swim-
up method, and a single IUI using a volume of 0.3 mL was done 36 hours after hCG injection
Pregnancy was documented by the serum hCG level, 2 weeks after IUI. When pregnant, a transvaginal ultrasound
examination was carried out 2 to 4 weeks later
Outcomes No explicit prioritisation of outcomes by the primary study authors
Main outcome: pregnancy rate. Pregnancy was not defined. In the abstract, the authors mention clinical pregnancy
rates. According to the methods section, pregnancy was documented by a serum hCG level, 2 weeks after IUI. When
positive, a transvaginal examination was scheduled 2 to 4 weeks later. We assume that only clinical pregnancies,
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Moramezi 2012 (Continued)
defined by positive findings at transvaginal ultrasound after positive hCG testing, were counted as the main outcome
measure. The time point at which the main outcome was measured (clinical pregnancy) was not reported. We judged
that the clinical pregnancy rates were measured after one IUI cycle, since the number of women treated was 110 and
the number of IUI cycles was 114,±,2.07 in the control group and 106,±,1.92 in the intervention group.
Other outcomes: abortion rate - not defined, and hysteroscopy complications
Notes Did not report if participants had already had a hysteroscopy prior to the fertility assessment or not. No information
on endometrial biopsy or not at the time of the screening hysteroscopy. We repeatedly contacted the corresponding
author (Dr Masoud Hemadi) but failed to obtain further clarification
hCG =
Characteristics of ongoing studies [ordered by study ID]
NCT02245750
Trial name or title Value of routine hysteroscopy prior to IVF/ICSI cycles
Methods Randomized controlled trial
Participants Women with recurrent implantation failure planned for IVF
Inclusion Criteria: patient’s age ranged from 20 to 40 years; normal appearance of the uterine cavity on
hysterosalpingography; patients prepared for IVF/ICSI cycle. Exclusion Criteria: Patients who have any con-
traindications for hysteroscopy. (menstruation, pregnancy, severe vaginitis or cervicitis, endometrial infection,
and history of pelvic inflammatory diseases); patients with uterine cavity pathology previously known to the
examiner; patients with previous uterine surgery, such as myomectomy; patients with abnormal HSG
Interventions Hysteroscopy with endometrial injury
Outcomes Live birth, clinical pregnancy rates
Starting date August 2014
Contact information ahmadmarzok85@gmail.com
Notes We tried contacting the authors but did not get any response regarding status of the trial
NCT03173404
Trial name or title Benefits of hysteroscopy prior to performing a cycle of in vitro fertilization/intracytoplasmic sperm injection
Methods Randomized controlled trial
Participants Women scheduled for their first or second IVF/ICSI cycle and with no abnormality detected in transvaginal
ultrasound examination
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NCT03173404 (Continued)
Inclusion criteria:
• Women with infertility, primary infertility
• Women who are about to start an IVF/ICSI cycle with their own eggs
• Age: 18 to 40 years
• Women in whom a multiple follicular development will be developed with a short protocol with
antagonists, or long with agonists, and starting dose of gonadotropins according to clinical criteria
• Women with uterine ultrasound without endometrial pathology
Exclusion criteria:
• Ovarian reserve: antimullerian hormone < 0.5 ng/dL or count of antral follicles < 5 between both
ovaries
• Myomatous uterus: presence of > 2 myomas > 4 cm, or that deform uterine cavity
• Uterine malformations
• Body mass index (BMI) < 18 or > 30
• Polycystic ovarian syndrome: according to European Society of Human Reproduction and
Embryology (ESRHE)/Rotterdam 2003 criteria
• Moderate-severe endometriosis
• Background or presence of pelvic inflammatory disease
• Hydrosalpinx not excised or occluded
• Hyperprolactinemia, defined as prolactin levels greater than 50 ng/mL
• Diagnostic history of endometrial hyperplasia
• Severe male factor: severe oligoasthenoteratozoospermia with a sperm cell count (REM) < 100,000
spermatozoa/mL
• Impossibility to apply the treatments provided by the study in the terms established by the protocol
• Contraindication for the use of any of the treatments provided in the study
Interventions Hysteroscopy before IVF
Outcomes Biochemical pregnancy, ongoing pregnancy, and live birth rates
Starting date 2014
Contact information La Paz University, Madrid. No contact email address or author name provided
Notes We could not identify author names or email ID to contact for status of the study
PACTR201402000691997
Trial name or title Role of hysteroscopy before first trial ICSI: a prospective randomized controlled trial
Methods Randomized controlled trial
Participants Women undergoing first IVF
Inclusion criteria: no previous IVF/ICSI cycle
Exclusion criteria: antral follicle count (AFC) 4
Anti-mullarian hormone (AMH) 0.7
Detectable uterine pathology by ultrasound
Age minimum: 20 years
Age maximum: 40 years
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PACTR201402000691997 (Continued)
Interventions Hysteroscopy before IVF
Outcomes Clinical pregnancy, miscarriage rate
Starting date June 2013
Contact information hassanmaghraby@gmail.com
Notes Status: ongoing recruitment on trial registry. We contacted one of the authors, but could not get confirmation
on status of the trial
UMIN000025679
Trial name or title Technique with intrauterine fiberscope and curettage of the endometrium (IFCE) improves the pregnancy
rate for infertile patients with repeated embryo implantation failures - a randomized controlled trial
Methods Randomized controlled trial
Participants Women with recurrent implantation failure planned for IVF
Women age: 18 to 50 years
BMI - 18.5 to 30
Normal ovarian reserve: AFC = 8 ; FSH < 8
Exclusion: severe male factor
Interventions Hysteroscopy with endometrial scratch
Outcomes Clinical pregnancy rate
Starting date 2014
Contact information funabiki m@oakclinic-group.com
Notes We contacted the authors for data. The authors were currently doing data reanalysis and could not provide
the necessary data for inclusion in the current review
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D A T A A N D A N A L Y S E S
Comparison 1. Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to conceive sponta-
neously
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 1 200 Risk Ratio (M-H, Fixed, 95% CI) 4.3 [2.29, 8.07]
2 Adverse outcomes 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Clinical pregnancy 1 200 Risk Ratio (M-H, Fixed, 95% CI) 3.8 [2.31, 6.24]
4 Miscarriage 1 200 Risk Ratio (M-H, Fixed, 95% CI) 2.8 [1.05, 7.48]
Comparison 2. Screening hysteroscopy versus no hysteroscopy in women before IVF
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 6 2745 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.11, 1.43]
1.1 Unselected 1 217 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.63, 2.40]
1.2 First IVF 2 953 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.96, 1.49]
1.3 Two or more IVF failures 3 1575 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.10, 1.53]
2 Adverse outcomes 4 1872 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.47 [0.15, 376.42]
2.1 Unselected 1 217 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 First IVF 2 953 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.47 [0.15, 376.42]
2.3 Two or more IVF failures 1 702 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Clinical pregnancy 10 3750 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.20, 1.45]
3.1 Unselected 3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.07, 1.84]
3.2 First IVF 3 1173 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.02, 1.41]
3.3 Two or more IVF failures 4 1996 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.21, 1.56]
4 Miscarriage 3 1669 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.67, 1.50]
4.1 Unselected 1 217 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.12, 68.33]
4.2 First IVF 1 750 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.59, 2.80]
4.3 Two or more IVF failures 1 702 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.55, 1.42]
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Analysis 1.1. Comparison 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to
conceive spontaneously, Outcome 1 Live birth.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to conceive spontaneously
Outcome: 1 Live birth
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Seyam 2015 43/100 10/100 100.0 % 4.30 [ 2.29, 8.07 ]
Total (95% CI) 100 100 100.0 % 4.30 [ 2.29, 8.07 ]
Total events: 43 (Hysteroscopy), 10 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no hysteroscopy Favours hysteroscopy
Analysis 1.2. Comparison 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to
conceive spontaneously, Outcome 2 Adverse outcomes.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to conceive spontaneously
Outcome: 2 Adverse outcomes
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Seyam 2015 0/100 0/100 Not estimable
Total (95% CI) 100 100 Not estimable
Total events: 0 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no hysteroscopy Favours hysteroscopy
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Analysis 1.3. Comparison 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to
conceive spontaneously, Outcome 3 Clinical pregnancy.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to conceive spontaneously
Outcome: 3 Clinical pregnancy
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Seyam 2015 57/100 15/100 100.0 % 3.80 [ 2.31, 6.24 ]
Total (95% CI) 100 100 100.0 % 3.80 [ 2.31, 6.24 ]
Total events: 57 (Hysteroscopy), 15 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 5.27 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no hysteroscopy Favours hysteroscopy
Analysis 1.4. Comparison 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to
conceive spontaneously, Outcome 4 Miscarriage.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 1 Screening hysteroscopy versus no hysteroscopy in subfertile women wishing to conceive spontaneously
Outcome: 4 Miscarriage
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Seyam 2015 14/100 5/100 100.0 % 2.80 [ 1.05, 7.48 ]
Total (95% CI) 100 100 100.0 % 2.80 [ 1.05, 7.48 ]
Total events: 14 (Hysteroscopy), 5 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours hysteroscopy Favours no hysteroscopy
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Analysis 2.1. Comparison 2 Screening hysteroscopy versus no hysteroscopy in women before IVF, Outcome
1 Live birth.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 2 Screening hysteroscopy versus no hysteroscopy in women before IVF
Outcome: 1 Live birth
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unselected
Juul Hare 2018 17/112 13/105 4.4 % 1.23 [ 0.63, 2.40 ]
Subtotal (95% CI) 112 105 4.4 % 1.23 [ 0.63, 2.40 ]
Total events: 17 (Hysteroscopy), 13 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 First IVF
Smit 2016 71/373 75/377 24.7 % 0.96 [ 0.72, 1.28 ]
Elsetohy 2015 58/102 33/101 11.0 % 1.74 [ 1.25, 2.41 ]
Subtotal (95% CI) 475 478 35.7 % 1.20 [ 0.96, 1.49 ]
Total events: 129 (Hysteroscopy), 108 (No hysteroscopy)
Heterogeneity: Chi2 = 7.30, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.63 (P = 0.10)
3 Two or more IVF failures
El-Toukhy 2016 102/350 102/352 33.7 % 1.01 [ 0.80, 1.27 ]
Aghahosseini 2012 50/142 45/211 12.0 % 1.65 [ 1.17, 2.32 ]
Rama Raju 2006 72/255 44/265 14.3 % 1.70 [ 1.22, 2.37 ]
Subtotal (95% CI) 747 828 59.9 % 1.30 [ 1.10, 1.53 ]
Total events: 224 (Hysteroscopy), 191 (No hysteroscopy)
Heterogeneity: Chi2 = 9.11, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 3.12 (P = 0.0018)
Total (95% CI) 1334 1411 100.0 % 1.26 [ 1.11, 1.43 ]
Total events: 370 (Hysteroscopy), 312 (No hysteroscopy)
Heterogeneity: Chi2 = 16.34, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 0.35, df = 2 (P = 0.84), I2 =0.0%
0.5 0.7 1 1.5 2
Favours no hysteroscopy Favours hysteroscopy
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Analysis 2.2. Comparison 2 Screening hysteroscopy versus no hysteroscopy in women before IVF, Outcome
2 Adverse outcomes.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 2 Screening hysteroscopy versus no hysteroscopy in women before IVF
Outcome: 2 Adverse outcomes
Study or subgroup Hysteroscopy No hysteroscopy
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unselected
Juul Hare 2018 0/112 0/105 Not estimable
Subtotal (95% CI) 112 105 Not estimable
Total events: 0 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 First IVF
Elsetohy 2015 0/102 0/101 Not estimable
Smit 2016 1/373 0/377 100.0 % 7.47 [ 0.15, 376.42 ]
Subtotal (95% CI) 475 478 100.0 % 7.47 [ 0.15, 376.42 ]
Total events: 1 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 Two or more IVF failures
El-Toukhy 2016 0/350 0/352 Not estimable
Subtotal (95% CI) 350 352 Not estimable
Total events: 0 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 937 935 100.0 % 7.47 [ 0.15, 376.42 ]
Total events: 1 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours hysteroscopy Favours no hysteroscopy
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Analysis 2.3. Comparison 2 Screening hysteroscopy versus no hysteroscopy in women before IVF, Outcome
3 Clinical pregnancy.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 2 Screening hysteroscopy versus no hysteroscopy in women before IVF
Outcome: 3 Clinical pregnancy
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unselected
El-Nashar 2011 25/62 15/62 2.9 % 1.67 [ 0.98, 2.84 ]
Juul Hare 2018 28/112 20/105 4.0 % 1.31 [ 0.79, 2.18 ]
Shawki 2012 40/120 30/120 5.8 % 1.33 [ 0.89, 1.99 ]
Subtotal (95% CI) 294 287 12.6 % 1.40 [ 1.07, 1.84 ]
Total events: 93 (Hysteroscopy), 65 (No hysteroscopy)
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
2 First IVF
Alleyassin 2017 53/110 42/110 8.1 % 1.26 [ 0.93, 1.71 ]
Elsetohy 2015 68/102 44/101 8.5 % 1.53 [ 1.18, 1.99 ]
Smit 2016 86/373 87/377 16.7 % 1.00 [ 0.77, 1.30 ]
Subtotal (95% CI) 585 588 33.3 % 1.20 [ 1.02, 1.41 ]
Total events: 207 (Hysteroscopy), 173 (No hysteroscopy)
Heterogeneity: Chi2 = 5.33, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.21 (P = 0.027)
3 Two or more IVF failures
Aghahosseini 2012 72/142 64/211 9.9 % 1.67 [ 1.29, 2.17 ]
Demirol 2004 67/210 45/211 8.6 % 1.50 [ 1.08, 2.07 ]
El-Toukhy 2016 121/350 116/352 22.3 % 1.05 [ 0.85, 1.29 ]
Rama Raju 2006 109/255 70/265 13.2 % 1.62 [ 1.27, 2.07 ]
Subtotal (95% CI) 957 1039 54.1 % 1.37 [ 1.21, 1.56 ]
Total events: 369 (Hysteroscopy), 295 (No hysteroscopy)
Heterogeneity: Chi2 = 10.64, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 4.99 (P < 0.00001)
Total (95% CI) 1836 1914 100.0 % 1.32 [ 1.20, 1.45 ]
Total events: 669 (Hysteroscopy), 533 (No hysteroscopy)
Heterogeneity: Chi2 = 17.48, df = 9 (P = 0.04); I2 =49%
Test for overall effect: Z = 5.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.96, df = 2 (P = 0.38), I2 =0.0%
0.5 0.7 1 1.5 2
Favours no hysteroscopy Favours hysteroscopy
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Analysis 2.4. Comparison 2 Screening hysteroscopy versus no hysteroscopy in women before IVF, Outcome
4 Miscarriage.
Review: Screening hysteroscopy in subfertile women and women undergoing assisted reproduction
Comparison: 2 Screening hysteroscopy versus no hysteroscopy in women before IVF
Outcome: 4 Miscarriage
Study or subgroup Hysteroscopy No hysteroscopy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unselected
Juul Hare 2018 1/112 0/105 1.2 % 2.81 [ 0.12, 68.33 ]
Subtotal (95% CI) 112 105 1.2 % 2.81 [ 0.12, 68.33 ]
Total events: 1 (Hysteroscopy), 0 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 First IVF
Smit 2016 14/373 11/377 24.7 % 1.29 [ 0.59, 2.80 ]
Subtotal (95% CI) 373 377 24.7 % 1.29 [ 0.59, 2.80 ]
Total events: 14 (Hysteroscopy), 11 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.53)
3 Two or more IVF failures
El-Toukhy 2016 29/350 33/352 74.2 % 0.88 [ 0.55, 1.42 ]
Subtotal (95% CI) 350 352 74.2 % 0.88 [ 0.55, 1.42 ]
Total events: 29 (Hysteroscopy), 33 (No hysteroscopy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 835 834 100.0 % 1.01 [ 0.67, 1.50 ]
Total events: 44 (Hysteroscopy), 44 (No hysteroscopy)
Heterogeneity: Chi2 = 1.07, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.07, df = 2 (P = 0.59), I2 =0.0%
0.02 0.1 1 10 50
Favours hysteroscopy Favours no hysteroscopy
55Screening hysteroscopy in subfertile women and women undergoing assisted reproduction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Cycle characteristics of included trials
Study ID Population Previous HSG
or hysteroscopy
Intervention Addi-
tional endome-
trial biopsy
Detected abnor-
malities treated
Timing of hys-
teroscopy
Seyam 2015 Unexplained in-
fertility of 2 years
duration
Normal HSG Hysteroscopy No Yes Follicular phase
Aghahosseini
2012
Twoormore IVF
failures
Normal
HSG; no hys-
teroscopy in pre-
vious 2 months
Hysteroscopy No No details No details avail-
able
Alleyassin 2017 First IVF Normal HSG;
women with his-
tory of
hysteroscopy ex-
cluded.
Hysteroscopy No Yes Preceding cycle;
luteal phase
Demirol 2004 Twoormore IVF
failures
Normal
HSG; no details
of history of hys-
teroscopy
Hysteroscopy No Yes Preceding cycle;
follicular phase
El-Nashar 2011 Unselected IVF
population
No de-
tails of HSG; no
details of history
of hysteroscopy
Hysteroscopy Yes Yes No details
Elsetohy 2015 First IVF Normal
HSG; no details
of history of hys-
teroscopy
Hysteroscopy No Yes Within 3 months
of IVF; follicular
phase
El-Toukhy 2016 Twoormore IVF
failures
Hysteroscopy
done within two
months were ex-
cluded; Included
womenwith pre-
vious history of
hys-
teroscopy (45%
in hysteroscopy
group vs 44% in
control)
Hysteroscopy No Yes;
(only one partial
septum not
treated).
Preceding cycle;
follicular phase
Juul Hare 2018 One IVF failure No details avail-
able
Hysteroscopy Yes No details avail-
able
No details avail-
able
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Table 1. Cycle characteristics of included trials (Continued)
Rama Raju 2006 Twoormore IVF
failures
Normal
HSG; no details
of history of hys-
teroscopy
Hysteroscopy Yes Yes Preceding cycle;
follicular phase
Shawki 2012 Unselected IVF
population
Normal
HSG; no details
of history of hys-
teroscopy
Hysteroscopy Those with suspi-
cious lesion after
injecting methy-
lene blue were
biopsied
Yes No details avail-
able
Smit 2016 First IVF Excluded
those with previ-
ous hysteroscopy
Hysteroscopy No Yes; (31/43 ab-
normali-
ties treated; 5 sep-
tum and 2 sub-
mucous fibroids
not treated)
1 to 3 months be-
fore IVF; follicu-
lar phase
IVF: in vitro fertilisation
HSG: hysterosalpingography
A P P E N D I C E S
Appendix 1. Cochrane Gynaecology and Fertility Group (CGFG) Specialised Register search
strategy
Searched 05 September 2018
Procite platform
Keywords CONTAINS “hysteroscopic ”or “hysteroscope diameter” or “hysteroscope size” or “hysteroscopy” or “hysteroscopy, tech-
niques” or “hysteroscopy-second look” or “hysterscope” or “uterine cavity assessment” or “mini-hysteroscopy” or “minihysteroscopy” or
“endometrial polypectomy” or “endometrial polyps” or “endoscopy” or Title CONTAINS “hysteroscopic ”or “hysteroscope diameter”or
“hysteroscope size” or “hysteroscopy” or “hysteroscopy, techniques” or “hysteroscopy-second look” or “hysteroscope” or “uterine cavity
assessment” or “mini-hysteroscopy” or “mini hysteroscopy” or “endometrial polypectomy” or “endometrial polyps” or “endoscopy”
AND
Keywords CONTAINS “IVF” or “ICSI” or “subfertility” or “in vitro fertilisation” or “in vitro fertilization” or “intracytoplasmic sperm
injection” or “assisted conception” or “assisted reproduction” or “ART” or “infertility” or “IUI” or “Intrauterine Insemination” or
“artificial insemination” or “ovarian hyperstimulation” or “ovarian stimulation” or “ovulation induction” or “COH” or “controlled
ovarian ” or “insemination” or “insemination-intrauterine” or “subfertility-female” or “IUI” or “recurrent miscarriage” or “pregnancy”
or Title CONTAINS “IVF” or “ICSI” or “subfertility” or “in vitro fertilisation” or “in vitro fertilization” or “intracytoplasmic sperm
injection” or “assisted conception” or “assisted reproduction” or “ART” or “infertility” or “IUI” or “Intrauterine Insemination” or
“artificial insemination” or “ovarian hyperstimulation” or “ovarian stimulation” or “ovulation induction” or “COH” or “controlled
ovarian ” or “insemination” or “insemination-intrauterine” or “subfertility-female” or “IUI” or “pregnancy” (162 hits)
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Appendix 2. CENTRAL via Central Register of Studies Online (CRSO)
Searched 05 September 2018
Web platform
#1 MESH DESCRIPTOR Hysteroscopy EXPLODE ALL TREES 355
#2 Hysteroscop*:TI,AB,KY 1056
#3 Uteroscop*:TI,AB,KY 0
#4 minihysteroscop*:TI,AB,KY 10
#5 (Uter* adj3 Endoscop*):TI,AB,KY 9
#6 #1 OR #2 OR #3 OR #4 OR #5 1063
#7 MESH DESCRIPTOR Infertility, Female EXPLODE ALL TREES 1228
#8 MESH DESCRIPTOR Reproductive Techniques, Assisted EXPLODE ALL TREES 2977
#9 (subfertil* or infertil*):TI,AB,KY 6142
#10 (IVF or ICSI):TI,AB,KY 4909
#11 (artificial insemination):TI,AB,KY 189
#12 (assisted reproducti*):TI,AB,KY 1030
#13 (intrauterine insemination):TI,AB,KY 801
#14 IUI:TI,AB,KY 641
#15 pregnancy:TI,AB,KY 35148
#16 conception:TI,AB,KY 1071
#17 fertility:TI,AB,KY 2490
#18 MESH DESCRIPTOR Abortion, Habitual EXPLODE ALL TREES 252
#19 miscarriage*:TI,AB,KY 1151
#20 (pregnancy loss):TI,AB,KY 359
#21 conceive:TI,AB,KY 280
#22 MESH DESCRIPTOR Gynatresia EXPLODE ALL TREES 16
#23 Gynatresia:TI,AB,KY 16
#24 (implant* adj3 failure*):TI,AB,KY 1056
#25 IVF-ET:TI,AB,KY 441
#26 (ovulation induction):TI,AB,KY 2122
#27 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR
#22 OR #23 OR #24 OR #25 OR #26 41363
#28 #6 AND #27 324
Appendix 3. MEDLINE search strategy
Searched from 1946 to 05 September 2018
Ovid platform
1 exp Hysteroscopy/ (4409)
2 Hysteroscop$.tw. (6236)
3 Uteroscop$.tw. (13)
4 minihysteroscop$.tw. (22)
5 (Uter$ adj3 Endoscop$).tw. (86)
6 or/1-5 (7237)
7 exp Infertility/ (61724)
8 subfertil$.tw. (4619)
9 (IVF or ICSI).tw. (24871)
10 artificial insemination.tw. (6081)
11 assisted conception.tw. (1121)
12 intrauterine insemination.tw. (2231)
13 iui.tw. (1583)
14 reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or
in vitro oocyte maturation techniques/ or exp insemination, artificial/ or exp ovulation induction/ or exp superovulation/ (60827)
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15 exp Infertility, Female/ (27010)
16 Infertil$.tw. (54744)
17 pregnancy.tw. (346819)
18 conception.tw. (27848)
19 fertility.tw. (69691)
20 Abortion, Habitual/ (6515)
21 miscarriage$.tw. (11922)
22 recurrent pregnancy loss$.tw. (1670)
23 conceive.tw. (4654)
24 Gynatresia/ (176)
25 (implant$ adj3 failure$).tw. (7800)
26 IVF-ET.tw. (2164)
27 ovulation induction.tw. (3384)
28 or/7-27 (519949)
29 randomized controlled trial.pt. (467803)
30 controlled clinical trial.pt. (92620)
31 randomized.ab. (420714)
32 randomised.ab. (84006)
33 placebo.tw. (196717)
34 clinical trials as topic.sh. (184694)
35 randomly.ab. (296498)
36 trial.ti. (186948)
37 (crossover or cross-over or cross over).tw. (77529)
38 or/29-37 (1228103)
39 exp animals/ not humans.sh. (4493304)
40 38 not 39 (1130506)
41 6 and 28 and 40 (227)
Appendix 4. Embase search strategy
Searched from 1980 to 05 September 2018
Ovid platform
1 exp Hysteroscopy/ (10545)
2 Hysteroscop$.tw. (10349)
3 Uteroscop$.tw. (20)
4 minihysteroscop$.tw. (42)
5 (Uter$ adj3 Endoscop$).tw. (113)
6 or/1-5 (12891)
7 subfertil$.tw. (6172)
8 (IVF or ICSI).tw. (41929)
9 artificial insemination.tw. (5364)
10 assisted conception.tw. (1610)
11 intrauterine insemination.tw. (3295)
12 iui.tw. (2883)
13 Infertil$.tw. (74005)
14 pregnancy.tw. (402281)
15 conception.tw. (32699)
16 fertility.tw. (79564)
17 miscarriage$.tw. (19484)
18 recurrent pregnancy loss$.tw. (2820)
19 conceive.tw. (6360)
20 (implant$ adj3 failure$).tw. (10557)
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21 IVF-ET.tw. (2970)
22 ovulation induction.tw. (4680)
23 exp infertility/ or exp female infertility/ or exp infertility therapy/ (164673)
24 assisted reproducti$.tw. (19631)
25 exp intracytoplasmic sperm injection/ (18393)
26 exp artificial insemination/ (15778)
27 exp ovulation induction/ (13068)
28 exp superovulation/ (2593)
29 exp recurrent abortion/ (5281)
30 or/7-29 (613203)
31 6 and 30 (5090)
32 Clinical Trial/ (939390)
33 Randomized Controlled Trial/ (506064)
34 exp randomization/ (79110)
35 Single Blind Procedure/ (32096)
36 Double Blind Procedure/ (148976)
37 Crossover Procedure/ (56068)
38 Placebo/ (307810)
39 Randomi?ed controlled trial$.tw. (183941)
40 Rct.tw. (29057)
41 random allocation.tw. (1783)
42 randomly allocated.tw. (30135)
43 allocated randomly.tw. (2330)
44 (allocated adj2 random).tw. (792)
45 Single blind$.tw. (21113)
46 Double blind$.tw. (182169)
47 ((treble or triple) adj blind$).tw. (803)
48 placebo$.tw. (269794)
49 prospective study/ (463707)
50 or/32-49 (1904367)
51 case study/ (55585)
52 case report.tw. (348767)
53 abstract report/ or letter/ (1017866)
54 or/51-53 (1413483)
55 50 not 54 (1855981)
56 31 and 55 (722)
Appendix 5. PsycINFO search strategy
Searched from 1806 to 05 September 2018
Ovid platform
1 subfertil$.tw. (84)
2 (IVF or ICSI).tw. (558)
3 artificial insemination.tw. (251)
4 assisted conception.tw. (98)
5 intrauterine insemination.tw. (23)
6 iui.tw. (34)
7 Infertil$.tw. (3267)
8 pregnancy.tw. (35219)
9 conception.tw. (21249)
10 fertility.tw. (6592)
11 miscarriage$.tw. (1141)
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12 recurrent pregnancy loss$.tw. (13)
13 conceive.tw. (2967)
14 (implant$ adj3 failure$).tw. (46)
15 IVF-ET.tw. (17)
16 ovulation induction.tw. (21)
17 assisted reproducti$.tw. (871)
18 exp Infertility/ (2028)
19 exp Reproductive Technology/ (1716)
20 exp Spontaneous Abortion/ (786)
21 or/1-20 (66886)
22 Hysteroscop$.tw. (17)
23 21 and 22 (10)
Appendix 6. CINAHL search strategy
Searched from 1961 to 05 September 2018
EBSCO platform
# Query Results
S47 S32 AND S46 86
S46 S33 OR S34 or S35 or S36 OR S37 OR S38 OR S39OR S40
OR S41 OR S42 OR S43 OR S44 OR S45
1,255,218
S45 TX allocat* random* 9,040
S44 (MH “Quantitative Studies”) 20,289
S43 (MH “Placebos”) 10,837
S42 TX placebo* 52,077
S41 TX random* allocat* 9,040
S40 (MH “Random Assignment”) 50,529
S39 TX randomi* control* trial* 153,082
S38 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
972,341
S37 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 201
S36 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 201
S35 TX clinic* n1 trial* 227,629
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(Continued)
S34 PT Clinical trial 86,040
S33 (MH “Clinical Trials+”) 244,152
S32 S6 AND S31 598
S31 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
OR S29 OR S30
205,364
S30 TX ovulation induction 741
S29 TX IVF-ET 86
S28 TX (implant* N3 fail*) 2,614
S27 TX conceive 1,066
S26 TX (recurrent pregnancy loss) 289
S25 TX miscarriage 2,880
S24 (MM “Abortion, Habitual”) 263
S23 TX fertility 10,698
S22 TX conception 25,694
S21 TX pregnancy 180,252
S20 TX Infertil* 10,835
S19 TX superovulation 28
S18 (MM “Ovulation Induction”) 318
S17 TX (sperm injection* intracytoplasmic) 423
S16 (MM “Fertilization in Vitro”) 1,971
S15 (MH “Reproduction Techniques+”) 7,812
S14 TX iui 165
S13 TX intrauterine insemination 241
S12 TX assisted conception 376
62Screening hysteroscopy in subfertile women and women undergoing assisted reproduction (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
S11 (MM “Insemination, Artificial”) 283
S10 TX artificial insemination 551
S9 TX (IVF or ICSI) 2,380
S8 TX subfertil* 602
S7 (MM “Infertility”) OR (MM “Embryo Transfer”) 5,152
S6 S1 OR S2 OR S3 OR S4 OR S5 1,576
S5 TX (Uter* N3 Endoscop*) 30
S4 TX minihysteroscop* 2
S3 TX Uteroscop* 1
S2 TX Hysteroscop* 1,555
S1 (MM “Hysteroscopy”) 677
Appendix 7. Data extraction form
Study information
1. Ref ID
2. First author
3. Year
4. Published q No
5. Language
Criteria for eligibility YES NO
Patients: Couples undergoing hysteroscopy prior to IVF/ICSI q q
Intervention Screening/routine hysteroscopy
a) Prior to the first IVF/ICSI cycle
b) Prior to 2 or more failed IVF cycles
q q
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(Continued)
Comparison No hysteroscopy q q
Outcomes Primary:
Live-birth rate (per randomised couple)
Secondary:
Clinical pregnancy rate (per randomised couple; positive pregnancy
test, gestational sac on ultrasound)
Multiple pregnancy rate (per randomised couple)
Miscarriage rate (per randomised couple)
Congenital anomalies (per randomised couple)
Additional:
q
q
q
q
q
q
q
q
q
q
q
q
q
q
q
q
q
q
Study characteristics
Design
1. Study
design
RCT
Parallel (intervention vs control)
Cross-over (participants used as intervention and control group)
……………………………….
Quotes:
……………………………………………………………………………………………………………………………………………………………………………………
2. Setting Single-centre q Multicentre
Country:
.………………………………………………………………………………………………………………
Participants: in- and exclusion
3. Study
criteria for
patient in-
clusion
4. Study
criteria for
patient ex-
clusion
5. Descrip-
tion con-
trol/ com-
parison
treatment
……………………………………………………………………………………………………………………………………………………………………………………
Baseline characteristics
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(Continued)
Pre-
vious IVF
and/or
ICSI treat-
ment
Reported q Not reported
Intervention
Embryo transfer after IVF, ICSI
1. Time of randomisation during cycle Prior to commencement of treatment cycle
2. Nature of intervention Hysteroscopy
No hysteroscopy
3. Timing of intervention Late luteal phase in the preceding cycle
Follicular phase in the preceding cycle
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S O U R C E S O F S U P P O R T
Internal sources
• Cochrane South Asia, Prof BV Moses Centre for Evidence-Informed Health Care and Health Policy, Christian Medical College,
Vellore, India.
Protocol development and review completion workshops
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We renamed the first category of randomised comparisons ’A routine, screening hysteroscopy, including hysteroscopic treatment of any
detected uterine cavity abnormalities versus no hysteroscopy in subfertile women wishing to conceive spontaneously’.
Introduction of a second category of randomised comparisons, namely ’A routine, screening hysteroscopy, including hysteroscopic
treatment of any detected uterine cavity abnormalities versus no hysteroscopy before intrauterine insemination (IUI)’. The inclusion
of this category made the review more comprehensive.
We used ongoing pregnancy as a surrogate outcome for live birth when data for live birth were not available.
In the protocol, the planned sensitivity analysis was restricted to studies without high risk of bias (not at high risk of bias in any domain
and at low risk for randomisation procedures). We changed the eligibility to studies at low risk of bias (without high or unclear risk of
bias in any domain) as per recent Cochrane editorial guidelines.
In the protocol, the sensitivity analysis was planned only for primary outcomes but in the review, we conducted a sensitivity analysis
for a clinically important secondary outcome (clinical pregnancy rate). This was done to test the robustness of our findings.
In the protocol, the planned analyses were to have been done using a random-effects model. In this review, we conducted analyses using
a fixed-effect model.
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